Bionik Laboratories (BNKL) S-1 29 Oct 18 IPO registration Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Jun. 30, 2018
Document Information [Line Items]
Document Type	S1
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Current
Cash and cash equivalents	$ 959,704	$ 507,311	$ 543,650
Trade accounts receivable	370,180	212,730	383,903
Prepaid expenses and other receivables (Note 5)	485,438	433,655	228,047
Inventories (Note 6)	155,795	237,443	228,249
Due from related parties	18,547	18,897	18,731
Total Current Assets	1,989,664	1,410,036	1,402,580
Equipment (Note 7)	150,210	159,961	227,421
Technology and other assets (Note 4)	4,635,666	4,706,719	5,030,624
Goodwill (Note 4)	22,308,275	22,308,275	22,308,275
Total Assets	29,083,815	28,584,991	28,968,900
Current
Accounts Payable	736,141	724,673	784,771
Accrued liabilities	1,127,364	1,529,505	1,228,657
Customer advances	800	800	121,562
Demand Loans (Note 8)	0	51,479	330,600
Promissory Note Payable (Note 8)		0	236,548
Convertible Loans (Note 8)	1,692,187	0	2,017,488
Conversion Feature on Convertible Loans (Note 8)	1,455,655	0
Deferred revenue	129,784	122,667	98,624
Shares to be issued, stock options and warrants (Notes 10, 11 and 12)	0	5,692,853	0
Total Current Liabilities	5,141,931	8,121,977	4,818,250
Shareholders' Equity
Preferred Stock, Value	0	0	0
Common Shares, Value	1,928	1,664	645
Additional paid in capital	60,434,845	56,195,541	45,184,320
Deficit	(36,537,038)	(35,776,340)	(21,076,464)
Accumulated other comprehensive income	42,149	42,149	42,149
Total Shareholders' Equity	23,941,884	20,463,014	24,150,650
Total Liabilities and Shareholders' Equity	$ 29,083,815	$ 28,584,991	$ 28,968,900

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets [Parenthetical] - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Allowance for Doubtful Accounts Receivable, Current	$ 19,694	$ 19,694	$ 38,600
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	250,000,000	150,000,000
Common Stock, Shares, Issued	1,652,495	1,368,856	325,901
Common Stock, Shares, Outstanding	1,652,495	1,368,856	325,901
Common Stock, Other Shares, Issued	275,146	295,146	319,396
Common Stock, Other Shares, Outstanding	275,146	295,146	319,396
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1	1
Preferred Stock, Shares Issued	1	1	1
Preferred Stock, Shares Outstanding	1	1	1

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Sales	$ 501,333	$ 87,520	$ 987,431	$ 571,945
Cost of Sales	253,163	29,300	402,665	388,756
Gross Margin	248,170	58,220	584,766	183,189
Operating expenses
Sales and marketing	542,659	445,525	1,989,837	1,188,207
Research and development	676,743	685,909	2,825,200	2,663,146
General and administrative	979,479	627,606	3,585,484	3,346,230
Share-based compensation expense (Notes 10 and 11)	595,412	251,048	1,540,580	1,001,950
Amortization of technology and other assets (Note 4)	71,053	92,949	323,905	550,080
Depreciation (Note 7)	17,595	24,552	89,026	79,868
Total operating expenses	2,882,941	2,127,589	10,354,032	8,829,481
Other (income) expense
Foreign exchange	(41,134)	98,561	102,999	71,573
Accretion expense (Note 8)	134,251	0	1,937,308	0
Fair value adjustment (Note 8)	44,087	0
Interest expense (Note 8)			1,297,205	43,735
Share premium (Note 8)			1,249,994	0
(Gain) loss on mark to market revaluation	(2,048,697)	0	376,674	0
Other expense	37,420	72,588
Other income			(107,656)	(692,198)
Total other (income) expenses	(1,874,073)	171,149	4,856,524	(576,890)
Net loss and comprehensive loss for the period	$ (760,698)	$ (2,240,518)	$ (14,625,790)	$ (8,069,402)
Loss per share - basic and diluted (Note 16)			$ (21.73)	$ (13.19)
Weighted average number of shares outstanding - basic and diluted (Note 16)			673,203	611,900
Loss per share - basic	$ (0.44)	$ (3.47)		$ (13.19)
Loss per share - diluted	$ (0.44)	$ (3.47)		$ (13.19)
Weighted average number of shares outstanding - basic	1,716,728	646,396
Weighted average number of shares outstanding - diluted	1,716,728	646,396

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Opening Balance at Mar. 31, 2016	$ 5,399,851	$ 0	$ 484	$ 18,364,280	$ (13,007,062)	$ 42,149
Opening Balance (in shares) at Mar. 31, 2016		1	483,942
Shares issued to acquire IMT	23,177,000	$ 0	$ 158	23,176,842	0	0
Shares issued to acquire IMT (in shares)			157,667
Stock compensation acquired	2,582,890	0	$ 0	2,582,890	0	0
Options exercised	18,166	0	$ 1	18,165	0	0
Options exercised (in shares)			734
Cashless exercise of warrants (Note 2)	0	0	$ 0	0	0	0
Cashless exercise of warrants (Note 2) (in shares)			342
Warrants exercised	40,195	0	$ 1	40,194	0	0
Warrants exercised (in shares)			1,165
Share compensation expense	1,001,950	0	$ 1	1,001,949	0	0
Share compensation expense (in shares)			1,447
Net loss for the period	(8,069,402)	0	$ 0	0	(8,069,402)	0
Closing Balance at Mar. 31, 2017	24,150,650	$ 0	$ 645	45,184,320	(21,076,464)	42,149
Closing Balance (in shares) at Mar. 31, 2017		1	645,297
Warrants exercised	1,125,038	$ 0	$ 34	1,125,004	0	0
Warrants exercised (in shares)			33,335
Share compensation expense	251,048	0	$ 0	251,048	0	0
Fair value of warrants on convertible loans	204,790	0	0	204,790	0	0
Net loss for the period	(2,240,518)	0	0	0	(2,240,518)	0
Closing Balance at Jun. 30, 2017	23,491,008	$ 0	$ 679	46,765,162	(23,316,982)	42,149
Closing Balance (in shares) at Jun. 30, 2017		1	678,632
Opening Balance at Mar. 31, 2017	24,150,650	$ 0	$ 645	45,184,320	(21,076,464)	42,149
Opening Balance (in shares) at Mar. 31, 2017		1	645,297
Warrants exercised	1,125,038	$ 0	$ 34	1,125,004	0	0
Warrants exercised (in shares)			33,335
Share compensation expense	1,540,580	0	$ 0	1,540,580	0	0
Fair value of warrants on convertible loans	548,179	0	0	548,179	0	0
Warrant down round feature	0	0	0	74,086	(74,086)	0
Conversion of convertible notes	9,180,785	0	$ 985	9,179,800	0	0
Conversion of convertible notes (in shares)			985,370
Stock option and warrant reclassification (Notes 11 & 12)	(2,845,557)	0	$ 0	(2,845,557)	0	0
Beneficial conversion feature on convertible debt (Note 8)	(1,389,129)	0	0	1,389,129		0
Net loss for the period	(14,625,790)	0	0	0	(14,625,790)
Closing Balance at Mar. 31, 2018	20,463,014	$ 0	$ 1,664	56,195,541	(35,776,340)	42,149
Closing Balance (in shares) at Mar. 31, 2018		1	1,664,002
Opening Balance at Jun. 30, 2017	23,491,008	$ 0	$ 679	46,765,162	(23,316,982)	42,149
Opening Balance (in shares) at Jun. 30, 2017		1	678,632
Share compensation expense	1,289,532	$ 0	$ 0	1,289,532	0	0
Fair value of warrants on convertible loans	343,389	0	0	343,389	0	0
Warrant down round feature	0	0	0	74,086	(74,086)	0
Conversion of convertible notes	9,180,785	0	$ 985	9,179,800	0	0
Conversion of convertible notes (in shares)			985,370
Stock option and warrant reclassification (Notes 11 & 12)	(2,845,557)	0	$ 0	(2,845,557)	0	0
Beneficial conversion feature on convertible debt (Note 8)	1,389,129	0	0	1,389,129	0	0
Net loss for the period	(12,385,272)	0	0	0	(12,385,272)	0
Closing Balance at Mar. 31, 2018	20,463,014	$ 0	$ 1,664	56,195,541	(35,776,340)	42,149
Closing Balance (in shares) at Mar. 31, 2018		1	1,664,002
Share compensation expense	595,412	$ 0	$ 0	595,412	0	0
Conversion of convertible notes	2,470,622	0	$ 264	2,470,358	0	0
Conversion of convertible notes (in shares)			263,639
Stock option and warrant reclassification (Notes 11 & 12)	1,173,534	0	$ 0	1,173,534	0	0
Net loss for the period	(760,698)	0	0	0	(760,698)	0
Closing Balance at Jun. 30, 2018	$ 23,941,884	$ 0	$ 1,928	$ 60,434,845	$ (36,537,038)	$ 42,149
Closing Balance (in shares) at Jun. 30, 2018		1	1,927,641

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 21, 2016	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Operating activities
Net loss for the period		$ (760,698)	$ (2,240,518)	$ (14,625,790)	$ (8,069,402)
Adjustment for items not affecting cash:
Depreciation		17,595	24,552	89,026	79,868
Amortization of intangible assets		71,053	92,949	323,905	550,080
Interest expense		36,702	72,766	1,294,005	41,934
Share based compensation expense		595,412	251,048	1,540,580	844,162
Accretion expense		134,251	0	1,937,308	0
Fair value adjustment		44,087	0
Shares issued for services				0	157,788
Share premium				1,249,994	0
(Gain) loss on mark to market revaluation		(2,048,697)	0	376,674	0
Allowance for doubtful accounts		(19,694)	0	(19,694)	0
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities		(1,929,989)	(1,799,203)	(7,833,992)	(6,395,570)
Changes in non-cash working capital items:
Accounts receivable		(137,756)	248,977	190,867	(377,413)
Prepaid expenses and other receivables		(51,783)	55,996	(205,608)	20,525
Due from related parties		350	(635)	(166)	22,714
Inventories		81,648	(27,297)	(9,194)	(39,370)
Accounts payable		11,468	104,648	(60,098)	(375,572)
Accrued liabilities		(402,141)	(5,428)	304,048	18,674
Customer advances		0	108,300	(120,762)	35,075
Deferred revenue		7,117	7,985	24,043	98,624
Net cash (used in) operating activities		(2,421,086)	(1,306,657)	(7,710,862)	(6,992,313)
Investing activities
Acquisition of equipment		(7,844)	(15,600)	(21,567)	(170,790)
Net cash (used in) investing activities		(7,844)	(15,600)	(21,567)	(170,790)
Financing activities
Proceeds from convertible loans		2,934,298	500,000	7,111,375	2,000,000
Proceeds on exercise of warrants		0	1,125,038	1,125,038	40,195
Repayment of Demand notes principal		(50,000)	0	(208,359)	0
Repayment of Demand notes interest		(2,975)	0	(79,259)	0
Cash acquired on acquisition				0	266,635
Proceeds from the exercise of options				0	18,166
Repayment of Promissory notes principal				(200,000)	0
Repayment of Promissory notes interest				(49,505)	0
Proceeds from short term loan				400,000	0
Repayment of short term loan				(400,000)	0
Repayment of short term loan interest				(3,200)	0
Net cash provided by financing activities		2,881,323	1,625,038	7,696,090	2,324,996
Net increase (decrease) in cash and cash equivalents for the period		452,393	302,781	(36,339)	(4,838,107)
Cash and cash equivalents, beginning of period	$ 5,381,757	507,311	543,650	543,650	5,381,757
Cash and cash equivalents, end of period		$ 959,704	$ 846,431	$ 507,311	$ 543,650
Assets acquired and liabilities assumed at April 21, 2016:
Current assets, including cash of $266,635	478,843
Equipment	59,749
Intangible assets	5,580,704
Goodwill	22,308,275
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory Notes payable	(217,808)
Bionik advance	(1,436,164)
Non-cash consideration	$ 25,759,890

Condensed Consolidated Interi_6

Condensed Consolidated Interim Statements of Cash Flows [Parenthetical]	1 Months Ended
	Apr. 21, 2016USD ($)
Cash Acquired from Acquisition	$ 266,635

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018 the Company implemented a 1 for 150 reverse split of the common and exchangeable shares. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”), and Bionik Canada issued 333,334 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (“IMT”), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergeco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock. On June 12, 2018, the Company approved the authorization of a common share capital increase to 500,000,000 from 250,000,000. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Going Concern As at June 30, 2018, the Company had a working capital deficit of $3,152,267 (March 31, 2018 – $6,711,941) and an accumulated deficit of $36,537,038 (March 31, 2018 – $35,766,340) and the Company incurred a net loss and comprehensive loss of $760,698 for the three month period ended June 30, 2018 (June 30, 2017 – $2,240,518). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due, however the Company believes it has the support of its major shareholders who have provided convertible loans to meet the Company’s cash flow needs and to continue as a going concern. The Company hopes to raise sufficient cash in the next six months to meet the Company’s anticipated cash requirements for the 12 months thereafter. Sales of additional equity or equity-linked securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects the forgoing, or combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however if these conditions are not achieved, this will raise significant doubt about the Company’s ability to continue as a going concern. The accompanying consolidated interim financial statements do not include any adjustments to reflect the possible effects of recoverability and reclassification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated interim financial statements.	1. NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 333,334. Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition, the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc., Bionik, Inc. (the former IMT) and Bionik Canada. References to Drywave relate to the Company prior to the Merger. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and our wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock (Note 4). The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. The consolidated financial statements consolidate the Company and its wholly owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA 02472. Going Concern As at March 31, 2018, the Company had a working capital deficit of $6,711,941 (working capital deficit as at March 31, 2017, of $3,415,670) and an accumulated deficit of $35,776,340 (March 31, 2017 - $21,076,464) and the Company incurred a net loss and comprehensive loss of $14,625,790 for the year ended March 31, 2017 (March 31, 2017 – net loss of $8,069,402). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects the forgoing, or a combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. The consolidated financial statements do not include any adjustments related to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these consolidated financial statements.

BASIS OF PRESENTATION AND CHANG

BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Disclosure Text Block [Abstract]
Basis of Presentation and Change In Accounting Policies [Text Block]	2. BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY a) Basis of presentation: On or about August 7, 2018, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Bionik’s common stock and exchangeable shares at a ratio up to one-to-one hundred and fifty (1:150). On October 29, 2018, the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. All owners of record on October 29, 2018 received one issued and outstanding share of Bionik common stock or exchangeable share in exchange for one hundred and fifty issued and outstanding shares of Bionik common stock or Bionik exchangeable stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-one hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Bionik common stock, which remains at $0.001. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split. b) Change in accounting policy The FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments With Down Round Features II Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception , allows a financial instrument with a down-round feature to no longer automatically be classified as a liability solely based on the existence of the down-round provision. The update also means the instrument would not have to be accounted for as a derivative and be subject to an updated fair value measurement each reporting period. On consideration of the above factors, the Company elected to early adopt ASU 2017-11 on July 1, 2017. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other organizations, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The early adoption allows the Company to reduce the cost and complexity of updating the fair value measurement each reporting period and eliminate the unnecessary volatility in reported earnings created by the revaluation when the Company’s shares’ value changes. The Company presented the change in accounting policy through the retrospective application of the new accounting principle to all prior periods, as described in ASU No. 250-10-45-5, Accounting Changes and Error Corrections. The following financial statement line items for the periods indicated were affected by the change in accounting principle. Income statement Period ended June 30, 2017 As originally ‎ reported As adjusted Effect of change Sales $ 87,520 $ 87,520 $ - Cost of Sales 29,300 29,300 - Total operating expenses 2,127,589 2,127,589 - Total other expenses 175,953 171,149 (4,804 ) Net loss and comprehensive loss for the period (2,245,322 ) (2,240,518 ) 4,804 Statement of Cash Flows As originally ‎ reported As adjusted Effect of change Net loss for period $ (2,245,322 ) $ (2,240,518 ) $ 4,804 Adjustment for items not affecting cash and changes in non-cash working capital items 938,665 933,861 (4,804 ) Net cash used in operating activities (1,306,657 ) (1,306,657 ) - Net cash used in investing activities (15,600 ) (15,600 ) - Net cash provided by financing activities 1,625,038 1,625,038 - Net increase in cash and cash equivalents for the period 302,781 302,781 - Cash and cash equivalents, beginning of period 543,650 543,650 - Cash and cash equivalents, end of period 846,431 846,431 -	2. BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY a) Basis of presentation On or about August 7, 2018, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Bionik’s common stock and exchangeable shares at a ratio up to one-to-one hundred and fifty. On October 29, 2018, the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. All owners of record on October 29, 2018 received one issued and outstanding share of Bionik common stock or exchangeable share in exchange for one hundred and fifty issued and outstanding shares of Bionik common stock or Bionik exchangeable stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-one hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Bionik common stock, which remains at $0.001. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split. b) Change in accounting policy The FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments With Down Round Feature II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception On consideration of the above factors, the Company elected to early adopt ASU 2017-11 on July 1, 2017, the ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other organizations, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The early adoption allows the Company to reduce the cost and complexity of updating the fair value measurement each reporting period and eliminate the unnecessary volatility in reported earnings created by the revaluation when the Company’s shares’ value changes. The Company presented the change in accounting policy through the retrospective application of the new accounting principle to all prior periods, as described in ASU No. 250-10-45-5, Accounting Changes and Error Corrections. The following financial statement line items for the year ended March 31, 2017 were affected by the change in accounting principle. Income Statement As of As originally March 31, 2017 Effect reported As adjusted of change Sales $ 571,945 $ 571,945 $ - Cost of Sales 388,756 388,756 - Total operating expenses 8,829,481 8,829,481 - Total other expenses (4,709,718 ) (576,890 ) (4,132,828 ) Net income (loss) and comprehensive loss for the Period (3,936,574 ) (8,069,402 ) (4,132,828 ) Basic loss per share (6.00 ) (13.19 ) (7.50 ) Diluted loss per share (6.00 ) (13.19 ) (7.50 ) Balance sheet As a result of the accounting policy change, the Company’s deficit as of April 1, 2017 increased from ($15,588,554), as originally reported under ASU No. 2016-01, to ($21,076,464) using ASU No. 2017-11. As originally reported As at March 31, 2017 As adjusted Effect of change Balance Sheet Current assets $ 1,402,580 $ 1,402,580 $ - Capital assets 227,421 227,421 - Intangible assets 27,338,899 27,338,899 - Total assets $ 28,968,900 $ 28,968,900 $ - Warrant derivative liability 959,600 - (959,600 ) Other current liabilities 4,818,205 4,818,250 45 Total liabilities $ 5,777,805 $ 4,818,250 $ (959,555 ) Common stock 645 645 - Additional paid in capital 38,736,855 45,184,320 6,447,465 Deficit (15,588,554 ) (21,076,464 ) (5,487,910 ) Accumulated other comprehensive income 42,149 42,149 - Total shareholders’ equity $ 23,191,095 $ 24,150,650 $ 959,555 Total liabilities and shareholders’ equity $ 28,968,900 $ 28,968,900 $ - Statement of cash flows As originally reported As at As adjusted Effect of change Net income (loss) for year $ (3,936,574 ) $ (8,069,402 ) $ (4,132,828 ) Adjustment for items not affecting cash and changes in non-cash working capital items (3,055,739 ) 1,077,089 4,132,828 Net cash (used in) operating activities (6,992,313 ) (6,992,313 ) - Net cash (used in) investing activities (170,790 ) (170,790 ) - Net cash provided by financing activities 2,324,996 2,324,996 - Net (decrease) in cash and cash equivalents for the year (4,838,107 ) (4,838,107 ) - Cash and cash equivalents, beginning of year 5,381,757 5,381,757 - Cash and cash equivalents, end of year $ 543,650 $ 543,650 $ -

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2018. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. This is the first set of the Company’s unaudited condensed consolidated interim financial statements where ASU-2014-09 “Revenue from Contracts with Customers (Topic 606)” has been applied. The changes in accounting policies from those used in the Company’s unaudited condensed consolidated interim financial statements from the quarter ended June 30, 2018 are described below. Newly Adopted and Recently Issued Accounting Pronouncements Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the modified retrospective transition method The Company has adopted ASU-2014-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. As a result of the adoption of ASU-2014-09, the Company’s accounting policies have been updated. See “Revenue Recognition” below for these changes in accounting policies, as well as new disclosure requirements. The changes in accounting policies will also be reflected in the Company’s unaudited condensed consolidated interim financials statements as at the quarter ended June 30, 2018.” In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU-2016-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2016-15 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2107-9). The FASB issued the update to provide clarity and reduce the cost and complexity when applying guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modifications accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company has adopted ASU-2017-09 during the quarter ended June 30, 2018 and it did not have material effect on the consolidated financial position and the consolidated results of operations. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, on the first-in, first-out basis. Work-in-progress and finished goods consist of materials, labor and allocated overhead. Revenue Recognition The Company has adopted ASU-2014-09 with an initial application date of April 1, 2018. The updated accounting policies, the impact on the June 30, 2018 unaudited condensed consolidated interim financial statements and additional disclosures are detailed as follows: The Company determines revenue recognition through the following steps: a) identification of the contract with a customer; b) identification of the performance obligation in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in a contract with a customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by the customers that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. In the comparative period, revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there was significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods. Impact on the 2018 unaudited condensed consolidated interim financial statements ASU-2014-09 had no impact on the Company’s unaudited condensed consolidated interim statement of loss and comprehensive loss for the three month period ended June 30, 2018. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet amounted to $75,065 and $64,957 at June 30, 2018 and March 31, 2018, respectively. The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $10,108 of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three month period ended June 30, 2018 (June 30, 2017 $Nil). Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates are based on management’s best knowledge of current events and actions of the Company it may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets. Actual results could differ from these estimates. Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, due from related parties, demand loans, and convertible loans approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. This was reversed in the quarter ended June 30, 2018, when the Company’s authorized capital was increased from 250,000,000 to 500,000,000 and gain on mark to market valuation of $2,048,697 was recognized. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the quarter ended June 30, 2018.	3. SIGNIFICANT ACCOUNTING POLICIES Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. Although the Company’s analysis of the impact of the new revenue recognition guidance is not fully complete, management do not currently believe that such guidance will materially impact the aggregate amount and timing of revenue recognition subsequent to adoption, nor a significant cumulative adjustment to the consolidated balance sheet as of April 1, 2018; however, the Company will provide enhanced revenue recognition disclosures as required by the new standard. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted ASU-2016-09 during the year and it did not have material effect on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the consolidated statement of cash flows. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company does not expect the impact of adopting ASU 2017-09 to be material on its consolidated financial statements and related disclosures. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, which approximates actual cost, on the first-in first-out basis. Work in progress and finished goods consist of materials, labor and allocated overhead. Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the consolidated balance sheets and amounted to $64,957 at March 31, 2018 (March 31, 2017 - $64,957). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $Nil of expenses related to warranty expenses incurred and recorded this expense in cost of goods sold for the year ended March 31, 2018 (March 31, 2017 - $Nil). Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company, and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Equipment Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows: Computer & Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates based on management’s best knowledge of current events and actions of the Company may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets, inputs to the fair value of shares to be issued, stock options and warrants. Actual results could differ from these estimates. Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued liabilities, due from related parties, demand loans, convertible loans and promissory note payable approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year. Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segment are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Approximately 99% of the Company’s assets are US-based and all sales for the years ended March 31, 2018 and 2017 were made by the Company’s US subsidiary, Bionik, Inc. In addition, all of the Company’s technology and other assets and goodwill are connected to the acquisition by the Company in April 2016 of Bionik, Inc. Equipment connected to Bionik Inc. amounts to $120,910 and $39,051 is connected to equipment at the Company’s Canadian subsidiary Bionik Laboratories Inc. Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash. Research and Development The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred. Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations. Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants are excluded from the computation of diluted loss per share when their effect is anti-dilutive. Impairment of Long-Lived Assets The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. Goodwill and Indefinite Lived Intangible Assets The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill and indefinite lived intangible assets, consisting of the trademarks acquired (Note 4), are assessed for impairment annually, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill or indefinite lived intangible assets. The Company performs impairment tests using a fair value approach when necessary. None of the Company’s goodwill or indefinite lived intangibles was impaired as of March 31, 2018. Accordingly, no impairment loss has been recognized in the year ended March 31, 2018.

ACQUISITION, TECHNOLOGY AND OTH

ACQUISITION, TECHNOLOGY AND OTHER ASSETS	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition on April 21, 2016 and the asset amortization period and expense for the three month period ended June 30, 2018 and the year ended March 31, 2018: Value Expense Value at Expense Value at Intangible Amortization acquired March 31, 2018 March 31, 2018 June 30, 2018 June 30, 2018 assets acquired period (years) $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,126 1,045,530 33,522 1,012,008 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 35,792 1,117,751 Non-compete agreement 2 61,366 30,709 1,739 1,739 - Assembled Workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 71,053 4,635,666 Amortization for the quarter ended June 30, 2017 was $92,949.	4. ACQUISITION On April 21, 2016, the Company acquired 100% of the common and preferred shares of IMT, through a transaction where Bionik Mergerco merged with and into IMT, with IMT surviving the merger as a wholly owned subsidiary of Bionik. Bionik issued an aggregate of 157,667 shares of Company Common Stock in exchange for all shares of IMT Common Stock and IMT Preferred Stock outstanding immediately prior to April 21, 2016. All shares have been issued at March 31, 2017. Bionik also assumed each of the 3,895,000 options to acquire IMT Common Stock granted under IMT’s equity incentive plan or otherwise issued by IMT. These options were exchanged for purchase of an aggregate of 20,000 options of Company Common Stock, of which 6,667 options have an exercise price of $37.50 per share, 6,667 options have an exercise price of $142.50 per share and 6,666 options have an exercise price of $157.50 per share. Stock compensation expense on vested options of $2,582,890 was recorded on the options exchanged and this amount is included in the acquisition equation. As a result of the acquisition of IMT, the Company acquired assets including three licensed patents, two license agreements, three FDA listed products, a FDA inspected manufacturing facility, extensive clinical and sales data, and international distributors. The Company retained an independent valuator to determine the purchase price allocation, which reflects the allocation of assets and goodwill. The following sets forth the purchase price allocation based on management’s best estimates of fair value, including a summary of major classes of consideration transferred and the recognized amounts of assets acquired and liabilities assumed at the acquisition date. As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299 ) Accrued liabilities (361,029 ) Customer deposits (86,487 ) Demand notes payable (324,894 ) Promissory notes payable (217,808 ) Bionik advance (d) (1,436,164 ) Net assets acquired (2,129,089 ) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $147.00 per share, which was the closing market price of the Company’s common stock on April 21, 2016. (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 11). (c) Pro forma information has not been presented for IMT as these operations have been consolidated for all days in the year ended March 31, 2017 except 20 days from April 20, 2016. These 20 days are not considered material. (d) Included in the net assets acquired was a loan issued to IMT in the amount of $300,000 under normal commercial terms. The loan carried an interest rate of 6% and were secured by all the assets of IMT subject to a $200,000 subordination to a third party financial services company, which was released in April 2016. (e) The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the year ended March 31, 2018: Amortization Value Expense Value at Expense Value at Intangible assets acquired period (years) acquired March 31, 2017 March 31, 2017 March 31, 2018 March 31, 2018 $ $ $ $ $ Patents and exclusive Licence Agreement 9.74 years 1,306,031 126,375 1,179,656 134,126 1,045,530 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 143,206 1,153,543 Non compete agreement 2 61,366 28,918 32,448 30,709 1,739 Assembled workforce 1 275,720 259,856 15,864 15,864 - 5,580,704 550,080 5,030,624 323,905 4,706,719

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	5. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, 2018 March 31, 2018 $ $ Prepaid expenses and sundry receivables 73,987 86,957 Prepaid inventory 261,626 301,104 Prepaid insurance 136,113 36,497 Sales taxes receivable (i) 13,712 9,097 485,438 433,655 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	5. PREPAID EXPENSES AND OTHER RECEIVABLES March 31, March 31, $ $ Prepaid expenses and other receivables 86,957 68,484 Prepaid inventory 301,104 - Prepaid insurance 36,497 136,896 Sales taxes receivable (i) 9,097 22,667 433,655 228,047 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. INVENTORIES June 30, 2018 March 31, 2018 $ $ Raw materials 124,795 237,443 Work in Progress 31,000 - 155,795 237,443 During the three month period ended June 30, 2018, the Company expensed $237,000 in inventory as cost of goods sold (June 30, 2017 –$29,300).	6. INVENTORY March 31, March 31, 2018 2017 $ $ Raw Materials 237,443 119,985 Work in Progress - 108,264 237,443 228,249 For the year ended March 31, 2018, $38,860 (March 31, 2017 - $43,009) of inventory has been written off to Cost of Sales as it is not expected to be used as a result of an introduction of new versions of existing InMotion products. In addition, for the year ended March 31, 2017, $124,416 was written off as a result of physical inventory counts.

EQUIPMENT

EQUIPMENT	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. EQUIPMENT Equipment consisted of the following as at June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 264,349 227,977 36,372 256,505 223,750 32,755 Furniture and fixtures 36,795 28,481 8,314 36,795 28,051 8,744 Demonstration equipment 200,186 116,798 83,388 200,186 105,441 94,745 Manufacturing equipment 88,742 85,819 2,923 88,742 85,668 3,074 Tools and parts 11,422 6,020 5,402 11,422 5,741 5,681 Assets under capital lease 23,019 9,208 13,811 23,019 8,057 14,962 624,513 474,303 150,210 616,669 456,708 159,961 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the period ended June 30, 2018 was $17,595 (June 30, 2017 $24,552)	7. EQUIPMENT Equipment consisted of the following as at March 31, 2018 and March 31, 2017: March 31, 2018 March 31, 2017 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 256,505 223,750 32,755 250,538 204,258 46,280 Furniture and fixtures 36,795 28,051 8,744 36,795 26,096 10,699 Demonstration equipment 200,186 105,441 94,745 184,586 44,420 140,166 Manufacturing equipment 88,742 85,668 3,074 88,742 84,982 3,760 Tools and parts 11,422 5,741 5,681 11,422 4,472 6,950 Assets under capital lease 23,019 8,057 14,962 23,019 3,453 19,566 Balance 616,669 456,708 159,961 595,102 367,681 227,421 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the year ended March 31, 2018 was $89,026 (March 31, 2017 - $79,868).

NOTES PAYABLE Demand Notes paya

NOTES PAYABLE Demand Notes payable	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. NOTES PAYABLE Demand Notes payable The Company had outstanding notes payable (“Notes”) of $Nil at June 30, 2018 ($51,479 March 31, 2018) which was acquired when the Company bought IMT on April 21, 2016. The Notes and interest were repaid during the quarter. Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment 52,975 Balance, June 30, 2018 $ - Interest expense incurred on the Notes totaled $1,496 for the three month period ended June 30, 2018 (June 30, 2017 $2,341), which was included in accrued liabilities until it was paid off. Convertible Loans Payable During the quarter, the Company received loans totaling $2,965,971, which carry an interest rate of 1% per month of which $2,291,930 came from related parties. The loans and interest are convertible as of July 20, 2018 at a 10% discount to the 30 day weighted VWAP of the Company’s stock price. In the event the Company consummates a firm commitment or underwritten offering of its common stock by March 27, 2019, and the price per share thereof (the “ Offering Price The schedules below reflect the fair value and anti-dilution features of the convertible loans, which resulted in accretion expense of $134,251 and a fair value adjustment of $44,087 being expensed for the three months ended June 30, 2018 (June 30, 2017 - $Nil and $Nil). At issuance Conversion feature fair value At June 30, 2018 Principal Beneficial Anti-dilution Fair value of Accretion Interest Ending Convertible promissory note $ 2,965,971 $ 368,936 $ 1,042,632 $ 1,554,403 $ 134,251 $ 3,533 $ 1,692,187 Conversion feature fair value Beneficial Anti-dilution Total At Issuance $ 368,936 $ 1,042,632 $ 1,411,568 Fair value adjustment 60,304 (16,217 ) 44,087 Ending balance at June 30, 2018 $ 429,240 $ 1,026,415 $ 1,455,655	8. NOTES PAYABLE (a) Demand Notes payable Notes Payable The Company repaid on December 31, 2017, all outstanding demand notes payable (“Notes”) except Notes in the aggregate principal amount of $50,000, which was deferred to June 30, 2018 acquired from IMT on April 21, 2016. Balance, March 31, 2016 $ - Acquisition of IMT (Note 4) 324,894 Accrued interest 5,706 Balance, March 31, 2017 330,600 Accrued interest 8,497 Repayment of principal (208,359 ) Repayment of interest (79,259 ) Balance, March 31, 2018 $ 51,479 Interest expense incurred on the Notes totaled $8,497 for the year ended March 31, 2018 (March 31, 2017 - $5,706), which are included in accrued liabilities. (b) Promissory Notes payable In February 2014, the Company borrowed $200,000 from an existing investor under the terms of a secured promissory note (“Promissory Note”). The Promissory Note bears interest at a simple interest rate equal to 10% per annum and interest is payable quarterly. Interest expenses incurred on the Promissory Note totaled $12,957 for the twelve months ended March 31, 2018 (March 31, 2017 - $18,740). The Promissory Note was paid in full during the quarter ended March 31, 2018 Balance, March 31, 2016 $ - Acquisition of IMT 217,808 Accrued Interest 18,740 Balance, March 31, 2017 236,548 Accrued interest 12,957 Repayment of principal (200,000 ) Repayment of interest (49,505 ) Balance, March 31, 2018 $ - (c) Short term Loan In December 2017, a company controlled by a Board member made a short-term loan to the Company of $400,000 with interest at 1.5% per month. Interest expenses incurred on the loan totaled $3,200 for the year ended March 31, 2018 (March 31, 2017 - $Nil). The Company repaid this loan with interest of $3,200 in January 2018. (d) Convertible Loans Payable In December 2016, several shareholders of the Company agreed to advance the Company $1,500,000 of convertible notes in three tranches: $500,000 upon origination of the convertible loans and $500,000 on each of January 15, 2017 and February 15, 2017. A further $500,000 was advanced in March 2017 to bring the total of these convertible loans to approximately $2,000,000. The convertible loans bore interest at 6% until the original due date of March 31, 2017 and $17,488 was accrued and expensed as interest on these loans for the year ended March 31, 2017. The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000; if no such equity financing is completed by November 15, 2017, then the loans shall become secured by a general security agreement over all assets of the Company; and, upon a change in control would either be payable on demand or convertible at the lesser of a price per share equal to that received by the parties in the change in control transaction or the market price of the shares. These conversion features were analyzed and determined to be contingent conversion features, accordingly, until the triggering event no beneficial conversion feature is recognized. On August 14, 2017, the Company entered into an amendment to these convertible loans, whereby the interest was changed to a fixed rate of 12% per year from April 1, 2017 to August 14, 2017, and 3% per month from August 14, 2017 to maturity, which was extended to the earlier of March 31, 2018 or consummation of a qualified financing. The conversion feature was modified to contain the following terms: upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of $7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to 25% of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) $0.25. Further, the Company issued warrants to these debt holders amounting to 20% of the aggregate principal of the convertible loans divided by the exercise price, which would be determined as the lowest of a new round stock in a qualified financing, the average volume weighted average price for the sixty trading days prior to January 31, 2018 or $0.25 per share. The warrants have a term of five years. These amendments were treated as an extinguishment of the original debt; however, there was no gain or loss recognized and the new and amended debts were recognized as shown below. An additional $2,999,975 was received from these shareholders during the year ended March 31, 2018 for a total of $4,999,975. For the year ended March 31, 2018, an additional $1,037,067 of interest was accrued and expensed on these convertible loans. The Company has recognized a discount against the convertible loans for the relative fair value of the warrants and is accreting the discount using the effective interest rate method. The assumptions used in valuing the warrants using the binomial valuation model were as follows: exercise price of $0.25 per share, volatility of 114%, risk-free interest rate of 1.91% and a term of five years. The Company evaluated the fair value of the warrants attached to the convertible notes as $548,178 and recorded $548,178 of accretion expense in the twelve months period ended March 31, 2018. Balance, March 31, 2016 $ - Additional principal investment 2,000,000 Accrued Interest 17,488 Balance, March 31, 2017 2,017,488 Additional principal investment 2,999,975 Fair value of warrants (548,178 ) Accretion expense 548,178 Accrued Interest 1,037,067 Conversion of principal and interest (6,054,530 ) Balance, March 31, 2018 $ - (e) Balance, March 31, 2017 $ - Additional principal investment 500,000 Accrued Interest 33,556 Conversion of principal and interest (533,556 ) Balance, March 31, 2018 $ - (f) $ 3,611,400 was received from these investors during the twelve months ended March 31, 2018 and $ 201,928 of interest was accrued and expensed on these convertible loans for the twelve months ended March 31, 2018 . Balance, March 31, 2017 - Additional principal investment 3,611,400 Accrued Interest 201,928 Conversion of principal and interest (3,813,328 ) Balance, March 31, 2018 $ - (g) Conversion of Notes Payable March 31, 2018 Principal Interest Premium Total Beneficial Number of Convertible Notes Payable (December 2016 to December 2017) $ 4,999,975 $ 1,054,555 $ 1,249,994 $ 7,304,523 $ 762,301 779,461 Chinese Convertible Loan $ 500,000 $ 33,556 - $ 533,556 $ 76,230 62,629 Convertible Notes Payable (December 2017 to March 2018) $ 3,611,400 $ 201,928 - $ 3,813,328 $ 550,598 406,918 Total $ 9,111,375 $ 1,290,039 $ 1,249,994 $ 11,651,407 $ 1,389,129 1,249,008

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. RELATED PARTY TRANSACTIONS AND BALANCES a) Due from related parties As at June 30, 2018, there was an outstanding loan to the Chief Technology Officer and director of the Company for $18,547 (March 31, 2018 – $18,897). The loan has an interest rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the period ended June 30, 2018, the Company accrued interest receivable in the amount of $59 (March 31, 2018 $590) and the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. b) Accounts payable and accrued liabilities As at June 30, 2018, $1,957 (March 31, 2018 $208,567) was owing to the CEO of the Company; $1,643 (March 31, 2018 $135,039) was owing to the Chief Technology Officer; and $920 (March 31, 2018 – $116,624) was owing to the Chief Financial Officer, all related to business expenses, all of which are included in accounts payable or accrued liabilities.	9. RELATED PARTY TRANSACTIONS AND BALANCES Due from related parties An outstanding loan to the Chief Operating Officer (“COO”) of the Company is for $18,897 (March 31, 2017 - $18,731). The loan has an interest rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the year ended March 31, 2018, the Company accrued interest receivable in the amount of $590 (March 31, 2017 - $707); the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. Accounts payable and accrued liabilities (a) As at March 31, 2018, $208,567 (March 31, 2017 - $Nil) was owing to the CEO of the Company; $135,039 (March 31, 2017 – $Nil to the former CTO) was owing to the Chief Technology Officer; and, $600 (March 31, 2017 – $97,500) was owing to the Chief Commercialization Officer, $116,624 (March 31, 2017 $Nil) was owing to the Chief Financial Officer (“CFO”), and $587,019 (March 31, 2017 – $4,135) was owing to the former CEO, all related to severance, bonuses and business expenses, all of which are included in accounts payable or accrued liabilities. Bonus amounts were paid in May 2018. (b) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, with a former director as a co- licenser, pursuant to which the Company pays the director and the co-licenser an aggregate royalty of 1% of sales based on patent #8,613,691. No sales have been made, as the technology under this patent has not been commercialized. (c) As at the effective date of the merger pursuant to the Merger Agreement, a former director received an aggregate of 34,603 shares of the Company in return for his ownership of IMT securities, in addition to his IMT options which were as of the effective date of the merger exercisable for an aggregate of 2,402 shares of common stock of the Company.

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. SHARE CAPITAL June 30, 2018 March 31, 2018 Number of Number of Shares $ Shares $ Exchangeable Shares: Balance beginning of year 295,146 295 319,396 319 Converted into common shares (a) (20,000 ) (20 ) (24,250 ) (24 ) Balance at the end of period 275,146 275 295,146 295 Common Shares Balance at beginning of the period 1,368,856 1,369 325,901 326 Shares issued to exchangeable shares 20,000 20 24,250 24 Shares issued on conversion of loans (b) 263,639 264 985,370 986 Warrants exercised - - 33,335 34 Balance at end of the period 1,652,495 1,653 1,368,856 1,369 TOTAL SHARES 1,927,641 1,928 1,664,002 1,664 a. During the three month period ended June 30, 2018, 20,000 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250 b. During the three month period ended June 30, 2018, 263,639 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss. c. On October 29, 2018, the Company completed a reverse stock split. Refer to Note 2(a) for details. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share, of the Company (the Special Voting Preferred Share”) to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as the Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.	10. SHARE CAPITAL March 31, 2018 March 31, 2017 Number of shares $ Number of shares $ Exchangeable Shares: Balance beginning of year 319,396 319 333,334 333 Converted into common shares (e) (24,250 ) (24 ) (13,938 ) (14 ) Balance at end of year 295,146 295 319,396 319 Common Shares Balance at beginning of the year 325,901 326 150,608 150 Shares issued on acquisition (Note 4) - - 157,667 157 Shares issued to exchangeable shareholders (e) 24,250 24 13,938 14 Shares issued for services (d) - - 1,447 2 Shares issued on conversion of loans (b) 985,370 986 - - Options exercised (Note 11) - - 734 1 Warrants exercised (a) 33,335 33 1,165 1 Cashless exercise of warrants (c) - - 342 1 Balance at end of the year 1,368,856 1,369 325,901 326 TOTAL SHARES 1,664,002 1,664 645,297 645 (a) During the year ended March 31, 2018, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $37.50 per share, and as a result, 33,335 common shares were issued for net proceeds of $1,125,038 (Note 12). (b) During the year ended March 31, 2018, the Company converted $9,171,604 of notes payable and interest into 985,370 common shares. Under the terms of this conversion the remaining $1,220,629 of principal and interest was required to be converted into 263,639 common shares, but were unable to be issued as a result of the Company not having enough authorized shares. The $2,470,622 value of these shares at March 31, 2018 has been classified as a liability until the common shares can be issued. In addition, there was a $376,674 loss recorded in the year connected to the difference of the $2,847,296 market value of the shares at March 31, 2018 and the value of these shares which resulted on the conversion of notes payable, the exercise price of which was based on a 30 day VWAP. (c) During the year ended March 31, 2017, 342 common shares were issued as a result of a cashless exercise of 1,747 warrants with an exercise price of $120.00. Under the terms of the warrant agreement the value of the warrants on exercise is attributed to the shares on exercise and the Company has recognized a value of $43,562. (d) The Company issued 1,447 common shares during the year ended March 31, 2017 for consulting services and recognized $59,500 of share compensation expense. (e) During the year ended March 31, 2018, 24,250 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2017 – 13,938 shares) (f) On October 29, 2018, the Company completed a one-for-one hundred and fifty to one (1:150) reverse stock consolidation. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into shares of common stock of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled.

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On November 24, 2015, the Company granted 4,334 options granted to employees that vest over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016, 1,667 options were cancelled and during the three month period ended June 30, 2018, $35,609 (June 30, 2017 $35,609) in stock compensation expense was recognized. On December 14, 2015, the Company granted 16,634 options to employees, directors and consultants that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. During the years ended March 31, 2016, 2017 and 2018, 167 options, 267 options and 2,912 options, respectively, were cancelled and for the three month period ended June 30, 2018, $41,350 (June 30, 2017 $100,289) of stock compensation expense was recognized. On April 21, 2016, the Company granted 20,000 stock options to employees of Bionik, Inc., the Company’s wholly-owned subsidiary (formerly IMT) in exchange for 3,895,000 options that existed before the Company purchased IMT of which 6,667 have an exercise price of $ 37.50 142.50 $10,169) has been recognized as stock compensation expense in the first quarter of 2018. On April 26, 2016, the Company granted 1,667 options to an employee with an exercise price of $150.00 per share that vest over three years at the anniversary date. The grant fair value was $213,750. During the quarter ended June 30, 2018, $17,813 (June 30, 2017- $17,813) was recognized as stock compensation expense. On August 8, 2016, the Company granted 5,000 options to an employee with an exercise price of $150.00 per share that vest over three years at the anniversary date. The grant fair value was $652,068. The employee left in April 2018 and 3,334 options that had not vested were cancelled and the remaining 1,667 options will expire in November 2018. During the quarter ended June 30, 2018, $18,113 (June 30, 2017 $54,339) of stock compensation expense was recognized. On February 6, 2017, the Company granted 2,667 options to an employee with an exercise price of $105.00 per share that vest over three years at the anniversary date. The grant fair value was $245,200. During the quarter ended June 30, 2018, $20,433 (June 30, 2017 $20,433) of stock compensation expense was recognized. On February 13, 2017, the Company granted 1,667 options to a consultant with an exercise price of $102.00 per share that vest over one and one-half years, every six months. The grant fair value was $148,750. During the quarter ended June 30, 2018, $12,396 (June 30, 2017 $12,396) of stock compensation expense was recognized. These options are now fully vested. On August 3, 2017, 10,000 options with an exercise price of $31.50 per share were granted to an executive officer, which vest equally over three future years. In addition, this executive officer was also granted up to 3,334 additional performance options based on meeting sales targets for the years ended March 31, 2018 and 2019. The grant value was $387,209 and $7,546 was expensed as stock compensation in the quarter. The executive left in April 2018 and all of these options were cancelled. On September 1, 2017, the Company granted 81,436 options with an exercise price of $24.15 per share equally to an executive officer and a consultant who is now the Chairman of the Company. Of such options, 13,573 vested and 50% of the remaining options vest on performance goals being met and 50% vest over 5 years. The grant fair value was $1,832,304 and during the quarter ended June 30, 2018, $38,173 in stock compensation expense was recognized. On January 24, 2018, the Company granted 24,267 options with an exercise price of $23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021, The grant fair value was $491,036 and during the quarter ended June 30, 2018, $39,703 in stock compensation expense was recognized. On April 20, 2018, the Company granted to an executive officer, 40,000 options with an exercise price of $9.74 per share that vest immediately with a 10-year expiry. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 10 years, expected volatility of 114% and a risk free rate of 1.59%. As these options fully vested on the grant date, $363,714 of stock based compensation was recognized during the quarter. On June 11, 2018, the Company granted to a newly-hired executive officer 5,000 options with an exercise price of $6.93 per share that vest over three years from the anniversary of the date of grant and expire in 7 years. The options were valued using the Black-Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk free rate of 1.59%. The grant fair value was $30,341 and $562 of stock compensation expense was recognized in the quarter. During the quarter ended June 30, 2018, the Company recorded $595,412 in share-based compensation related to the vesting of stock options (June 30, 2017 $251,048). The following is a summary of stock options outstanding and exercisable as of June 30, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 24.75 1,028 April 1, 2021 1,028 34.50 630 June 20, 2021 630 34.50 13,212 July 1, 2021 13,212 34.50 944 February 17, 2022 944 183.00 2,667 November 24, 2022 1,778 150.00 12,912 December 14, 2022 10,889 142.50 747 March 28, 2023 747 157.50 2,887 March 28, 2023 2,887 150.00 1,667 April 26, 2023 1,112 150.00 1,667 August 8, 2023 1,667 105.00 2,667 February 6, 2024 889 102.00 1,667 February 13, 2024 1,667 142.50 211 March 3, 2024 211 157.50 816 March 3, 2024 816 142.50 43 March 14, 2024 43 157.50 164 March 14,2024 164 142.50 485 September 30, 2024 485 157.50 1,876 September 30, 2024 1,876 142.50 24 June 2, 2025 24 157.50 90 June 2, 2025 90 37.50 442 December 30, 2025 442 142.50 328 December 30, 2025 182 24.15 81,436 September 1, 2027 13,573 23.25 22,434 January 24, 2025 - 9.735 40,000 April 19, 2028 40,000 6.93 5,000 June 10, 2025 - 196,044 95,356 The weighted-average remaining contractual term of the outstanding options was 7.89 (March 31, 2018 – 5.81) and for the options that are exercisable the weighted average was 7.38 (March 31, 2018 – 5.70)	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On November 24, 2015, the Company issued 4,334 options granted to employees that vest over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016, 1,667 options were cancelled and stock compensation expense of $62,317 was recognized. During the year ended March 31, 2018, $142,438, (March 31, 2017 -$142,438) in stock compensation expense was recognized. On December 14, 2015, the Company issued 16,634 options granted to employees, directors and consultants that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. During the year ended March 31, 2016, 167 options were cancelled and for the year ended March 31, 2017, 267 options were cancelled and for the year ended March 31, 2018, 2,912 options were cancelled, and the year ended March 31, 2018, $479,315, (March 31, 2017 - $407,208) of stock compensation expense was recognized. On April 21, 2016, the Company issued 20,000 s $2,582,890 $29,524, (March 31, 2017 -$102,989) On April 26, 2016, the Company issued 1,667 options to an employee with an exercise price of $150.00 per share that will vest over three years at the anniversary date. The grant fair value was $213,750. During the year ended March 31, 2018, $71,250, (March 31, 2017 - $66,104) was recognized as stock compensation expense. On August 8, 2016, the Company issued 5,000 options to an employee with an exercise price of $150.00 per share that will vest over three years at the anniversary date. The grant fair value was $652,068. During the year ended March 31, 2018, $217,356, (March 31, 2017 -$140,230) of stock compensation expense was recognized. On February 6, 2017, the Company issued 2,667 options to an employee with an exercise price of $105.00 per share that will vest over three years at the anniversary date. The grant fair value was $245,200. During the year ended March 31, 2018, $81,733, (March 31, 2017 - $12,163) of stock compensation expense was recognized. On February 13, 2017, the Company issued 1,667 options to a consultant with an exercise price of $102.00 per share that will vest over one and one- half years, every six months. The grant fair value was $148,750. During the year ended March 31, 2018, $49,583, (March 31, 2017 -$6,345) of stock compensation expense was recognized. On August 3, 2017, 10,000 options at $31.50 per share to an executive officer, which vest equally over three future years. In addition, this executive officer was also granted up to 3,334 additional performance options based on meeting sales targets for the years ending March 31, 2018 and 2019. The performance options will vest at market price if the performance objectives are met. This grant had a grant date fair value of $387,209 and a share compensation expense of $60,371 was recognized for the year ended March 31, 2018. These options were valued using the Black-Scholes model and the following inputs: expected life of 7 years, expected volatility 114% and a risk-free rate of 1.73%. On September 1, 2017, the Company granted 81,436 options at $24.15 per share equally to an executive officer and a consultant. 13,573 options have vested and 50% of the remaining options vest on performance being met and 50% vest annually over 5 years. The grant date fair value was $1,832,304 and $381,730 is the current expense for the year ended March 31, 2018. These options were valued using the Black-Scholes model and the following inputs: expected life of 10 years, expected volatility 114% and a risk-free rate of 1.91%. On January 24, 2018, the Company granted 24,267 options at $23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021. The grant fair value was $491,036 and $27,280 is the current stock compensation expense for the year ended March 31, 2018. These options were valued using the Black-Scholes model and the following inputs: expected life of 10 years, expected volatility 114% and a risk-free rate of 1.91%. During the year ended March 31, 2018, the Company recorded $1,540,580 in share-based compensation related to the vesting of stock options (March 31, 2017 - $844,162). The following is a summary of stock options outstanding and exercisable as of March 31, 2018: These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions: Expected life Risk free Dividend Forfeiture Expected Grant date Grant date in rate rate rate volatility fair February 17, 2015 3.89 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 3.25 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 3.22 1.59 % 0 % 0 % 114 % $ 118,957 April 1, 2014 3.01 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 4.65 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 4.71 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 6.11 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 5.07 1.59 % 0 % 0 % 114 % $ 213,750 August 8, 2016 5.36 1.59 % 0 % 0 % 114 % $ 652,068 February 6, 2017 5.86 1.59 % 0 % 0 % 114 % $ 245,200 February 13, 2017 5.88 1.59 % 0 % 0 % 114 % $ 148,750 August 3, 2017 6.35 1.59 % 0 % 0 % 114 % $ 387,209 September 1, 2017 9.43 1.59 % 0 % 0 % 114 % 1,832,304 January 24, 2018 6.82 1.59 % 0 % 0 % 114 % $ 491,036 Number of Options Weighted-Average Outstanding, March 31, 2017 66,024 88.50 Issued 119,036 23.25 Exercised - - Expired - - Cancelled (14,385 ) 97.50 Outstanding, March 31, 2018 170,675 75.00 The following is a summary of stock options outstanding and exercisable as of March 31, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 24.75 1,762 April 1, 2021 1,762 34.50 651 June 20, 2021 651 34.50 13,212 July 1, 2021 13,212 34.50 944 February 17, 2022 944 183.00 2,667 November 24, 2022 1,778 150.00 13,289 December 14, 2022 11,178 142.50 747 March 28, 2023 747 157.50 2,887 March 28, 2023 2,887 150.00 1,667 April 26, 2023 556 150.00 5,000 August 8, 2023 1,667 105.00 2,667 February 6, 2024 889 102.00 1,667 February 13, 2024 1,111 142.50 211 March 3, 2024 211 157.50 816 March 3, 2024 816 142.50 43 March 14, 2024 43 157.50 164 March 14, 2024 164 142.50 485 September 30, 2024 485 157.50 1,876 September 30, 2024 1,876 142.50 23 June 2, 2025 23 157.50 90 June 2, 2025 90 37.50 442 December 30, 2025 442 142.50 328 December 30, 2025 182 31.50 13,334 August 3, 2024 - 24.15 81,436 September 1, 2027 13,573 23.25 24,267 January 24, 2025 - 170,675 55,287 The weighted-average remaining contractual term of the outstanding options is 7.46 (March 31, 2017 – 5.12) and for the options that are exercisable the weighted average is 5.74 (March 31, 2017 – 6.02). Reclassification of Fair Value As the Company does not have sufficient authorized shares of common stock to cover its options issued, a valuation of these options was done at March 31, 2018 and the resulting liability of $1,451,393 has been recorded in the consolidated balance sheet as shares to be issued, stock options and warrants. Grant Date Expected Life Risk Free rate Dividend rate Forfeiture Rate Expected Volatility Remeasured February 17, 2015 3.89 1.59 % 0 % 0 % 135 % $ 7,122 July 1, 2014 3.25 1.59 % 0 % 0 % 135 % $ 90,472 June 20, 2014 3.22 1.59 % 0 % 0 % 135 % $ 4,428 April 1, 2014 3.01 1.59 % 0 % 0 % 135 % $ 12,437 November 24, 2015 4.65 1.59 % 0 % 0 % 135 % $ 16,327 December 14, 2015 4.71 1.59 % 0 % 0 % 135 % $ 85,833 April 21, 2016 6.39 1.59 % 0 % 0 % 118 % $ 53,853 April 26, 2016 5.07 1.59 % 0 % 0 % 114 % $ 11,430 August 8, 2016 5.36 1.59 % 0 % 0 % 114 % $ 35,722 February 6, 2017 5.86 1.59 % 0 % 0 % 114 % $ 16,969 February 13, 2017 5.88 1.59 % 0 % 0 % 114 % $ 10,703 August 3, 2017 6.35 1.59 % 0 % 0 % 114 % $ 109,970 September 1, 2017 9.43 1.59 % 0 % 0 % 114 % $ 782,966 January 24, 2018 6.82 1.59 % 0 % 0 % 114 % $ 213,161 1,451,393

WARRANTS

WARRANTS	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Exercise Price ($) Outstanding and exercisable, March 31, 2015 72,157 202.50 Issued 48,171 202.50 Exercised (992 ) (120.00 ) Outstanding and exercisable, March 31, 2016 119,336 202.50 Exercised (1,747 ) (120.00 ) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected to warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected to warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with the conversion of loans and interest into common shares 106,709 9.375 Issued in connection with the conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected to warrant transaction 136,388 73.02 Issued in connection with anti-dilution provision connected to warrant transaction 13,464 44.28 Outstanding at June 30, 2018 and March 31, 2018 365,974 53.19 * Adjusted to reflect a one-for-one hundred and fifty (1:150) reverse stock split effective October 29, 2018. During the year ended March 31, 2018, the Company consummated an offer to amend and exercise its outstanding warrants, enabling the holders of the warrants to exercise such warrants for $37.50 per share. The Company received net proceeds of $1,125,038. The Company also converted loans and interest due. Due to an anti-dilution clause in the warrant agreement for such outstanding warrants, an additional 559 warrants were issued to the $120.00 per share warrant holders and 6,275 warrants were issued to the $210.00 per share warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $120.00 per share to $112.35 per share and from $210.00 per share to $194.00 per share. Due to the anti-dilution clause in the warrant agreements for such outstanding warrants, an additional 13,464 warrants were issued to the $112.50 per share warrant holders and 136,388 warrants were issued to the $194.00 per share warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $112.50 per share to $44.28 per share and from $194.00 per share to $73.02 per share as a result of the loan and interest conversion for shares that have been issued at March 31, 2018 and shares that were issued on June 12, 2018. The Company measured the effects of the above two transactions, which triggered anti-dilution clause using the binomial tree model and recorded a loss of $74,086 against the deficit for the year ended March 31, 2018. The Company issued 2,667 warrants at $37.50 per share for four years expiring June 27, 2020 to the firm who facilitated the warrant offer. The Company issued 15,658 warrants at $90.00 per share which expire in 5 years on March 31, 2023 and 106,709 warrants at $9.375 per share which also expire March 31, 2023 in connection with the loan and interest conversion transaction. Common share purchase warrants The following is a summary of common share purchase warrants as of June 30, 2018: Exercise Number of Expiry Date 90.00 15,658 March 31, 2023 73.02 104,019 February 26, 2019 73.02 21,768 March 27, 2019 73.02 5,813 March 31, 2019 73.02 45,061 April 21, 2019 73.02 21,274 May 27,2019 73.02 20,782 June 30, 2019 44.28 22,223 February 26, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 365,974 . The weighted-average remaining contractual term of the outstanding warrants was 2.01 (March 31, 2018 – 2.27). The exercise price and number of underlying shares with respect the $73.02 per share and $44.25 per shares warrants are expected to be further adjusted pursuant to the anti-dilution provisions therein, as a result of any further common share issuances.	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Outstanding and exercisable, March 31, 2015 72,157 202.50 Issued 48,171 202.50 Exercised (992 ) (120.00 ) Outstanding and exercisable, March 31, 2016 119,336 202.50 Exercised (1,747 ) (120.00 ) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with conversion of loans and interest into common shares 106,709 9.375 Issued in connection with conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected with issuance of common shares 136,388 73.02 Issued in connection with anti-dilution provision connected with issuance of common shares 13,464 44.28 Outstanding and exercisable, March 31, 2018 365,974 $ 53.19 During the year ended March 31, 2018, the Company consummated an offer to amend and exercise its then outstanding warrants, enabling the holders of the warrants to exercise such warrants for $37.50 per share. The Company received net proceeds of $1,125,038. The Company also converted loans and interest due. Due to an anti-dilution clause in the warrant agreements for such outstanding warrants an additional 559 warrants were issued to the Due to an anti-dilution clause in the warrant agreements for such outstanding warrants an additional 13,464 warrants were issued to the $112.50 per share warrant holders and 136,388 warrants were issued to the $194.00 per share warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $112.35 per share to $44.28 per share and from $194.00 per share to $73.02 per share as a result of loan and interest conversion transaction for shares that have been issued and shares that will be issued. The Company measured the effects of the two above transactions, which triggered anti-dilution clause using the binomial tree model and recorded a loss of $74,086 against deficit. The Company issued 2,667 warrants exercisable at $37.50 The Company issued 15,658 warrants at $90.00 During the year ended March 31, 2017, a warrant holder exercised 1,747 342 shares of common stock. Common share purchase warrants The following is a summary of common share purchase warrants outstanding after the warrant offer to amend and exercise the additional warrant issue and the re-pricing of the warrants as of March 31, 2018. Exercise Price ($) Number of Warrants Expiry Date 90.00 15,658 March 31, 2023 73.02 104,019 February 26, 2019 73.02 21,768 March 27, 2019 73.02 5,813 March 31, 2019 73.02 45,061 April 21, 2019 73.02 21,274 May 27, 2019 73.02 20,782 June 30, 2019 44.28 22,223 February 26, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 365,974 The weighted-average remaining contractual term of the outstanding warrants was 2.27 (March 31, 2017 – 1.77). The exercise price and number of underlying shares with respect to the $73.02 per share and $44.28 per share warrants are expected to be further adjusted pursuant to the anti-dilution provisions therein, as a result of any further issuance of common shares. The Company was committed to issue to these third party previous lenders warrants exercisable into 2,331 Exchangeable Shares at an exercise price of $34.50 per share for a period ending March 21, 2017. During the year ended December 31, 2015, the Company issued these warrants. Reclassification of Fair Value As the Company does not have sufficient authorized shares of common stock to cover its warrants issued; a valuation of these warrants was done at March 31, 2018 and the resulting liability of $1,394,164 has been recorded in the consolidated balance sheets as shares to be issued, stock options and warrants. The 2,667 warrants at an exercise price of $37.50 per share issued in connection to the warrant transaction to the broker were not included in the fair value remeasurement because there is sufficient capital to convert them into common stock if exercised. Exercise Number of Expiry Date Expected life Risk free Dividend Forfeiture Expected Remeasured 90.00 15,658 31-Mar-23 5 1.59 % 0 % 0 % 135 % 116,142 73.02 104,019 26-Feb-19 0.92 1.59 % 0 % 0 % 135 % 100,281 73.02 21,768 27-Mar-19 1 1.59 % 0 % 0 % 135 % 24,815 73.02 5,813 31-Mar-19 1 1.59 % 0 % 0 % 135 % 6,769 73.02 45,061 21-Apr-19 1.08 1.59 % 0 % 0 % 135 % 58,358 73.02 21,274 27-May-19 1.16 1.59 % 0 % 0 % 135 % 32,276 73.02 20,782 30-Jun-19 1.25 1.59 % 0 % 0 % 135 % 36,116 44.28 22,223 26-Feb-19 0.92 1.59 % 0 % 0 % 135 % 38,423 9.375 64,025 14-Aug-22 4.38 1.59 % 0 % 0 % 135 % 593,355 9.375 42,684 31-Mar-22 4 1.59 % 0 % 0 % 135 % 387,529 363,307 1,394,164 Exchangeable share purchase warrants In 2014, the Company repaid loans of $180,940 plus accrued interest of $12,138 owing to investors introduced by Pope and Co. As part of this transaction in March 2017, 1,165 warrants were exercised for proceeds of $40,195 and the remaining 1,165 warrants expired.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. INCOME TAXES Components of net (loss) before income taxes consists of the following: March 31 March 31 $ $ U.S. (12,281,398 ) (6,056,384 ) Canada (2,344,392 ) (2,013,018 ) (14,625,790 ) (8,069,402 ) Net (loss) for the year before recovery of income taxes (14,625,790 ) (8,069,402 ) Statutory rate 34.04 % 35 % Expected income tax (recovery) expense (4,978,619 ) (2,824,291 ) Tax rate changes and other basis adjustments 1,748,278 44,238 Stock-based compensation 524,412 350,683 Difference in Foreign Tax Rates 184,414 - Accretion 659,458 - Share premium 425,497 - Non-deductible expense 339,296 (132,076 ) Net DTA acquired - (546,122 ) Change in valuation allowance 1,097,264 3,107,568 Recovery of income taxes - - The following deferred tax assets have not been recognized. Deferred tax reflects the tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities and consisted of the following: March 31, March 31, $ $ Equipment 70,350 73,520 Share issue costs 510 1,456 SR&ED pool 690,320 464,746 Other 535,510 629,266 Non-capital losses – Canada 2,515,170 2,067,203 Net operating losses – U.S. 4,331,850 4,534,710 Valuation allowance (7,017,430 ) (5,956,118 ) 1,126,280 1,814,783 Intangibles and other (1,126,280 ) (1,814,783 ) - - The Company has non-capital losses in its Canadian subsidiary of approximately $ 9,491,200 Income taxes are provided based on the liability method, which results in deferred tax assets and liabilities arising from temporary differences. Temporary differences are differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years. The liability method requires the effect of tax rate changes on current and accumulated deferred taxes to be reflected in the period in which the rate change was enacted. The liability method also requires that deferred tax assets be reduced by a valuation allowance unless it is more likely than not that the assets will be realized. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest accrued on uncertain tax positions as well as interest received from favorable tax settlements within interest expense. The Company recognizes penalties accrued on unrecognized tax benefits within general and administrative expenses. As of March 31, 2018, the Company had no uncertain tax positions. In many cases the Company’s uncertain tax positions are related to tax years that remain subject to examination by tax authorities. The following describes the open tax years, by major tax jurisdiction, as of March 31, 2018: United States – Federal 2014 – present United States – State 2014 – present Canada – Federal 2013 – present Canada – Provincial 2013 – present

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain, and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 1,753 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the former Chief Technology Officer and the new Chief Technology Officer had transferred 2,098 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former Chief Technology Officer and the new Chief Technology Officer 2,134 common shares collectively. As at June 30, 2018, these shares have not yet been issued. (b) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, pursuant to which the Company pays the licensors an aggregate royalty of 1% of sales based on patent #8,613,691. No sales were made on the technology under this patent as it has not yet been commercialized. One of the licensors is a founder of IMT and a former officer and director of the Company. (c) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form a China-based joint venture to commercialize the Company’s products (“China JV”) in which the Company has a 25% interest and the JV Partner has a 75% interest. The China JV entity formally was created on May 22, 2018. Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000, 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license. As of June 30, 2018, the JV Partner has not made the required $290,000 investment into the China JV. The China JV has entered into an office rent commitment in Tianjin, PRC for five years, for which the monthly rent payments expressed in USD are $10,083 for year one, $13,444 for year two and three and $14,141 for years four and five. An approximate $18,131 prepaid deposit was provided as part of the commitment. The operations of the China JV are currently financed by Bionik’s JV Partner and approximately $93,309 is due to them at June 30, 2018. Bionik is applying the equity method of accounting to determine the net income from the joint venture partnership. As of June 30, 2018, Bionik has not made any investments into the China JV. (d) On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at June 30, 2018.	14. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 1,753 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the Company’s then-CTO and COO had transferred 2,098 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former CTO and COO 2,134 common shares. As at March 31, 2018, these shares have not yet been issued. (b) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form China Bionik Medical Rehabilitation Technology Ltd. (“China JV”), in which the Company will have a 25% interest and the JV Partner 75%. The China JV was not formally formed until subsequent to year-end and there were no operations during the year ended March 31, 2018. Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 on the date of formation, $435,000 12 months later and $725,000, 60 months after the date of formation. The Company is required to contribute certain intellectual property. (c) On March 6, 2018, the Company signed a distribution agreement with Curexo Inc for South Korea and as part of this agreement the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed by Curexo. Inc.

RISK MANAGEMENT

RISK MANAGEMENT	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. RISK MANAGEMENT The Company’s cash balances are maintained in a bank in Canada and a USA bank. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits. Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.	15. RISK MANAGEMENT The Company’s cash balances are maintained in a bank in Canada and a USA Bank. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits. Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grant and investment tax credits received from the Government of Canada.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	16. LOSS PER SHARE Common stock equivalents (other than the Exchangeable Shares), options and warrants were excluded from the computation of diluted loss per share for the year ended March 31, 2018 and 2017, after retrospective adjustment for a change in accounting policy (Note 2), as their effects are anti-dilutive.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. SUBSEQUENT EVENTS On July 24, 2018, the Company’s Board of Directors (the “Board”) unanimously adopted resolutions authorizing a reverse stock split, at a ratio of up to 1:150, of the common stock of the Company. On or about August 7, 2018, a majority of the holders of the common stock and exchangeable shares of the Company, voting together as a single class, approved the reverse stock split. On September 25, 2018, the Board established the split ratio for the reverse stock split at a ratio of 1:150. On October 29, 2018, the Company effected the reverse stock split and thereafter the Company’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. Refer to details in Note 2(a). Subsequent to June 30, 2018, the Company converted $4,732,853 of convertible loans and interest into 683,396 common shares in accordance with their terms. As at July 20, 2018, 683,396 common shares were issued. Due to an anti-dilution clause in warrant agreements for certain outstanding warrants, an additional 67,952 warrants were issued to the $73.02 warrant holders and 6,305 warrants were issued to the $44.28 warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $73.02 to $55.71 and from $44.28 to $34.50 as a result of loan and interest conversion transaction for shares that have been issued as a result of the July 20, 2018 conversions described above.	17. SUBSEQUENT EVENTS (a) On July 24, 2018, the Company’s Board of Directors (the “Board”) unanimously adopted resolutions authorizing a reverse stock split, at a ratio of up to 1:150, of the common stock of the Company. On or about August 7, 2018, a majority of the holders of the common stock and exchangeable shares of the Company, voting together as a single class, approved the reverse stock split. On September 25, 2018, the Board established the split ratio for the reverse stock split at a ratio of 1:150. On October 29, 2018, the Company effected the reverse stock split and thereafter the Company’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. Further details are provided in Note 2(a). (b) Subsequent to , Exchangeable Shareholders exchanged exchangeable shares into Common Stock. (c) On June 11, 2018, the Company increased the number of authorized shares of Common Stock from 250,000,000 to 500,000,000 and issued 263,639 common shares related to the conversion of notes payable at March 31, 2018. (Note 10(b)) (d) Subsequent to March 31, 2018, the Company’s board granted 40,000 options at $9.735 per share that immediately vested to the CEO of the Company with a 10 year expiry and 5,000 options at $6.93 per share were granted to our Chief Commercial Officer that vest over three years from the anniversary of the grant and expire in 7 years. (e) Subsequent to March 31, 2018, an affiliate of one of the Company’s major shareholders who is also a director provided an aggregate amount of $1,960,000 in term loans to the Company that bears interest at a fixed rate of 1% per month and matures on April 30, 2019. (f) Subsequent to March 31, 2018, the China JV was formally formed and the Company will account for it as of the date of formation.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Accounting Policies [Abstract]
Consolidated Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2018. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. This is the first set of the Company’s unaudited condensed consolidated interim financial statements where ASU-2014-09 “Revenue from Contracts with Customers (Topic 606)” has been applied. The changes in accounting policies from those used in the Company’s unaudited condensed consolidated interim financial statements from the quarter ended June 30, 2018 are described below. Impact on the 2018 unaudited condensed consolidated interim financial statements ASU-2014-09 had no impact on the Company’s unaudited condensed consolidated interim statement of loss and comprehensive loss for the three month period ended June 30, 2018.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the modified retrospective transition method The Company has adopted ASU-2014-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. As a result of the adoption of ASU-2014-09, the Company’s accounting policies have been updated. See “Revenue Recognition” below for these changes in accounting policies, as well as new disclosure requirements. The changes in accounting policies will also be reflected in the Company’s unaudited condensed consolidated interim financials statements as at the quarter ended June 30, 2018.” In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU-2016-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2016-15 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2107-9). The FASB issued the update to provide clarity and reduce the cost and complexity when applying guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modifications accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company has adopted ASU-2017-09 during the quarter ended June 30, 2018 and it did not have material effect on the consolidated financial position and the consolidated results of operations.	Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. Although the Company’s analysis of the impact of the new revenue recognition guidance is not fully complete, management do not currently believe that such guidance will materially impact the aggregate amount and timing of revenue recognition subsequent to adoption, nor a significant cumulative adjustment to the consolidated balance sheet as of April 1, 2018; however, the Company will provide enhanced revenue recognition disclosures as required by the new standard. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted ASU-2016-09 during the year and it did not have material effect on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the consolidated statement of cash flows. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company does not expect the impact of adopting ASU 2017-09 to be material on its consolidated financial statements and related disclosures.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, on the first-in, first-out basis. Work-in-progress and finished goods consist of materials, labor and allocated overhead.	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, which approximates actual cost, on the first-in first-out basis. Work in progress and finished goods consist of materials, labor and allocated overhead.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company has adopted ASU-2014-09 with an initial application date of April 1, 2018. The updated accounting policies, the impact on the June 30, 2018 unaudited condensed consolidated interim financial statements and additional disclosures are detailed as follows: The Company determines revenue recognition through the following steps: a) identification of the contract with a customer; b) identification of the performance obligation in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in a contract with a customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by the customers that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. In the comparative period, revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there was significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods.	Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet amounted to $75,065 and $64,957 at June 30, 2018 and March 31, 2018, respectively. The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $10,108 of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three month period ended June 30, 2018 (June 30, 2017 $Nil).	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the consolidated balance sheets and amounted to $64,957 at March 31, 2018 (March 31, 2017 - $64,957). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $Nil of expenses related to warranty expenses incurred and recorded this expense in cost of goods sold for the year ended March 31, 2018 (March 31, 2017 - $Nil).
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.	Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company, and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Property, Plant and Equipment, Policy [Policy Text Block]		Equipment Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows: Computer & Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates are based on management’s best knowledge of current events and actions of the Company it may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets. Actual results could differ from these estimates.	Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates based on management’s best knowledge of current events and actions of the Company may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets, inputs to the fair value of shares to be issued, stock options and warrants. Actual results could differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, due from related parties, demand loans, and convertible loans approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. This was reversed in the quarter ended June 30, 2018, when the Company’s authorized capital was increased from 250,000,000 to 500,000,000 and gain on mark to market valuation of $2,048,697 was recognized. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the quarter ended June 30, 2018.	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued liabilities, due from related parties, demand loans, convertible loans and promissory note payable approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year.
Segment Reporting, Policy [Policy Text Block]		Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segment are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Approximately 99% of the Company’s assets are US-based and all sales for the years ended March 31, 2018 and 2017 were made by the Company’s US subsidiary, Bionik, Inc. In addition, all of the Company’s technology and other assets and goodwill are connected to the acquisition by the Company in April 2016 of Bionik, Inc. Equipment connected to Bionik Inc. amounts to $120,910 and $39,051 is connected to equipment at the Company’s Canadian subsidiary Bionik Laboratories Inc.
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash.
Research and Development Expense, Policy [Policy Text Block]		Research and Development The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred.
Income Tax, Policy [Policy Text Block]		Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations.
Earnings Per Share, Policy [Policy Text Block]		Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants are excluded from the computation of diluted loss per share when their effect is anti-dilutive.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Impairment of Long-Lived Assets The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.
Goodwill and Intangible Assets, Policy [Policy Text Block]		Goodwill and Indefinite Lived Intangible Assets The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill and indefinite lived intangible assets, consisting of the trademarks acquired (Note 4), are assessed for impairment annually, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill or indefinite lived intangible assets. The Company performs impairment tests using a fair value approach when necessary. None of the Company’s goodwill or indefinite lived intangibles was impaired as of March 31, 2018. Accordingly, no impairment loss has been recognized in the year ended March 31, 2018.

BASIS OF PRESENTATION AND CHA_2

BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Disclosure Text Block [Abstract]
Schedule of Changes in Accounting Policy [Table Text Block]	The following financial statement line items for the periods indicated were affected by the change in accounting principle. Income statement Period ended June 30, 2017 As originally ‎ reported As adjusted Effect of change Sales $ 87,520 $ 87,520 $ - Cost of Sales 29,300 29,300 - Total operating expenses 2,127,589 2,127,589 - Total other expenses 175,953 171,149 (4,804 ) Net loss and comprehensive loss for the period (2,245,322 ) (2,240,518 ) 4,804 Statement of Cash Flows As originally ‎ reported As adjusted Effect of change Net loss for period $ (2,245,322 ) $ (2,240,518 ) $ 4,804 Adjustment for items not affecting cash and changes in non-cash working capital items 938,665 933,861 (4,804 ) Net cash used in operating activities (1,306,657 ) (1,306,657 ) - Net cash used in investing activities (15,600 ) (15,600 ) - Net cash provided by financing activities 1,625,038 1,625,038 - Net increase in cash and cash equivalents for the period 302,781 302,781 - Cash and cash equivalents, beginning of period 543,650 543,650 - Cash and cash equivalents, end of period 846,431 846,431 -	The following financial statement line items for the year ended March 31, 2017 were affected by the change in accounting principle. Income Statement As of As originally March 31, 2017 Effect reported As adjusted of change Sales $ 571,945 $ 571,945 $ - Cost of Sales 388,756 388,756 - Total operating expenses 8,829,481 8,829,481 - Total other expenses (4,709,718 ) (576,890 ) (4,132,828 ) Net income (loss) and comprehensive loss for the Period (3,936,574 ) (8,069,402 ) (4,132,828 ) Basic loss per share (6.00 ) (13.19 ) (7.50 ) Diluted loss per share (6.00 ) (13.19 ) (7.50 ) Balance sheet As a result of the accounting policy change, the Company’s deficit as of April 1, 2017 increased from ($15,588,554), as originally reported under ASU No. 2016-01, to ($21,076,464) using ASU No. 2017-11. As originally reported As at March 31, 2017 As adjusted Effect of change Balance Sheet Current assets $ 1,402,580 $ 1,402,580 $ - Capital assets 227,421 227,421 - Intangible assets 27,338,899 27,338,899 - Total assets $ 28,968,900 $ 28,968,900 $ - Warrant derivative liability 959,600 - (959,600 ) Other current liabilities 4,818,205 4,818,250 45 Total liabilities $ 5,777,805 $ 4,818,250 $ (959,555 ) Common stock 645 645 - Additional paid in capital 38,736,855 45,184,320 6,447,465 Deficit (15,588,554 ) (21,076,464 ) (5,487,910 ) Accumulated other comprehensive income 42,149 42,149 - Total shareholders’ equity $ 23,191,095 $ 24,150,650 $ 959,555 Total liabilities and shareholders’ equity $ 28,968,900 $ 28,968,900 $ - Statement of cash flows As originally reported As at As adjusted Effect of change Net income (loss) for year $ (3,936,574 ) $ (8,069,402 ) $ (4,132,828 ) Adjustment for items not affecting cash and changes in non-cash working capital items (3,055,739 ) 1,077,089 4,132,828 Net cash (used in) operating activities (6,992,313 ) (6,992,313 ) - Net cash (used in) investing activities (170,790 ) (170,790 ) - Net cash provided by financing activities 2,324,996 2,324,996 - Net (decrease) in cash and cash equivalents for the year (4,838,107 ) (4,838,107 ) - Cash and cash equivalents, beginning of year 5,381,757 5,381,757 - Cash and cash equivalents, end of year $ 543,650 $ 543,650 $ -

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule Of Equipment Method [Table Text Block]	The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows: Computer & Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum

ACQUISITION, TECHNOLOGY AND O_2

ACQUISITION, TECHNOLOGY AND OTHER ASSETS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition on April 21, 2016 and the asset amortization period and expense for the three month period ended June 30, 2018 and the year ended March 31, 2018: Value Expense Value at Expense Value at Intangible Amortization acquired March 31, 2018 March 31, 2018 June 30, 2018 June 30, 2018 assets acquired period (years) $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,126 1,045,530 33,522 1,012,008 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 35,792 1,117,751 Non-compete agreement 2 61,366 30,709 1,739 1,739 - Assembled Workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 71,053 4,635,666	The following sets forth the purchase price allocation based on management’s best estimates of fair value, including a summary of major classes of consideration transferred and the recognized amounts of assets acquired and liabilities assumed at the acquisition date. As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299 ) Accrued liabilities (361,029 ) Customer deposits (86,487 ) Demand notes payable (324,894 ) Promissory notes payable (217,808 ) Bionik advance (d) (1,436,164 ) Net assets acquired (2,129,089 ) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $147.00 per share, which was the closing market price of the Company’s common stock on April 21, 2016. (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 11). (c) Pro forma information has not been presented for IMT as these operations have been consolidated for all days in the year ended March 31, 2017 except 20 days from April 20, 2016. These 20 days are not considered material. (d) Included in the net assets acquired was a loan issued to IMT in the amount of $300,000 under normal commercial terms. The loan carried an interest rate of 6% and were secured by all the assets of IMT subject to a $200,000 subordination to a third party financial services company, which was released in April 2016.
Business Acquisition, Pro Forma Information [Table Text Block]		(e) The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the year ended March 31, 2018: Amortization Value Expense Value at Expense Value at Intangible assets acquired period (years) acquired March 31, 2017 March 31, 2017 March 31, 2018 March 31, 2018 $ $ $ $ $ Patents and exclusive Licence Agreement 9.74 years 1,306,031 126,375 1,179,656 134,126 1,045,530 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 143,206 1,153,543 Non compete agreement 2 61,366 28,918 32,448 30,709 1,739 Assembled workforce 1 275,720 259,856 15,864 15,864 - 5,580,704 550,080 5,030,624 323,905 4,706,719

PREPAID EXPENSES AND OTHER RE_2

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, 2018 March 31, 2018 $ $ Prepaid expenses and sundry receivables 73,987 86,957 Prepaid inventory 261,626 301,104 Prepaid insurance 136,113 36,497 Sales taxes receivable (i) 13,712 9,097 485,438 433,655 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	March 31, March 31, $ $ Prepaid expenses and other receivables 86,957 68,484 Prepaid inventory 301,104 - Prepaid insurance 36,497 136,896 Sales taxes receivable (i) 9,097 22,667 433,655 228,047 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	June 30, 2018 March 31, 2018 $ $ Raw materials 124,795 237,443 Work in Progress 31,000 - 155,795 237,443	March 31, March 31, 2018 2017 $ $ Raw Materials 237,443 119,985 Work in Progress - 108,264 237,443 228,249

EQUIPMENT (Tables)

EQUIPMENT (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 264,349 227,977 36,372 256,505 223,750 32,755 Furniture and fixtures 36,795 28,481 8,314 36,795 28,051 8,744 Demonstration equipment 200,186 116,798 83,388 200,186 105,441 94,745 Manufacturing equipment 88,742 85,819 2,923 88,742 85,668 3,074 Tools and parts 11,422 6,020 5,402 11,422 5,741 5,681 Assets under capital lease 23,019 9,208 13,811 23,019 8,057 14,962 624,513 474,303 150,210 616,669 456,708 159,961	Equipment consisted of the following as at March 31, 2018 and March 31, 2017: March 31, 2018 March 31, 2017 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 256,505 223,750 32,755 250,538 204,258 46,280 Furniture and fixtures 36,795 28,051 8,744 36,795 26,096 10,699 Demonstration equipment 200,186 105,441 94,745 184,586 44,420 140,166 Manufacturing equipment 88,742 85,668 3,074 88,742 84,982 3,760 Tools and parts 11,422 5,741 5,681 11,422 4,472 6,950 Assets under capital lease 23,019 8,057 14,962 23,019 3,453 19,566 Balance 616,669 456,708 159,961 595,102 367,681 227,421

NOTES PAYABLE Demand Notes pa_2

NOTES PAYABLE Demand Notes payable (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Convertible Debt [Table Text Block]	Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment 52,975 Balance, June 30, 2018 $ -	Balance, March 31, 2016 $ - Additional principal investment 2,000,000 Accrued Interest 17,488 Balance, March 31, 2017 2,017,488 Additional principal investment 2,999,975 Fair value of warrants (548,178 ) Accretion expense 548,178 Accrued Interest 1,037,067 Conversion of principal and interest (6,054,530 ) Balance, March 31, 2018 $ -
Schedule of Short-term Debt [Table Text Block]		Balance, March 31, 2017 $ - Additional principal investment 500,000 Accrued Interest 33,556 Conversion of principal and interest (533,556 ) Balance, March 31, 2018 $ -
Schedule of Conversion of Notes Payable [Table Text Block]		March 31, 2018 Principal Interest Premium Total Beneficial Number of Convertible Notes Payable (December 2016 to December 2017) $ 4,999,975 $ 1,054,555 $ 1,249,994 $ 7,304,523 $ 762,301 779,461 Chinese Convertible Loan $ 500,000 $ 33,556 - $ 533,556 $ 76,230 62,629 Convertible Notes Payable (December 2017 to March 2018) $ 3,611,400 $ 201,928 - $ 3,813,328 $ 550,598 406,918 Total $ 9,111,375 $ 1,290,039 $ 1,249,994 $ 11,651,407 $ 1,389,129 1,249,008
Schedule of Convertible Debt Fair Value [Table Text Block]	At issuance Conversion feature fair value At June 30, 2018 Principal Beneficial Anti-dilution Fair value of Accretion Interest Ending Convertible promissory note $ 2,965,971 $ 368,936 $ 1,042,632 $ 1,554,403 $ 134,251 $ 3,533 $ 1,692,187
Schedule of Convertible Debt Beneficial Conversion Feature Table text Block [Table Text Block]	Conversion feature fair value Beneficial Anti-dilution Total At Issuance $ 368,936 $ 1,042,632 $ 1,411,568 Fair value adjustment 60,304 (16,217 ) 44,087 Ending balance at June 30, 2018 $ 429,240 $ 1,026,415 $ 1,455,655
Convertible Debt [Member]
Schedule of Short-term Debt [Table Text Block]		Balance, March 31, 2017 - Additional principal investment 3,611,400 Accrued Interest 201,928 Conversion of principal and interest (3,813,328 ) Balance, March 31, 2018 $ -
Demand Notes payable [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		Balance, March 31, 2016 $ - Acquisition of IMT (Note 4) 324,894 Accrued interest 5,706 Balance, March 31, 2017 330,600 Accrued interest 8,497 Repayment of principal (208,359 ) Repayment of interest (79,259 ) Balance, March 31, 2018 $ 51,479
Promissory Note [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		Balance, March 31, 2016 $ - Acquisition of IMT 217,808 Accrued Interest 18,740 Balance, March 31, 2017 236,548 Accrued interest 12,957 Repayment of principal (200,000 ) Repayment of interest (49,505 ) Balance, March 31, 2018 $ -

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	June 30, 2018 March 31, 2018 Number of Number of Shares $ Shares $ Exchangeable Shares: Balance beginning of year 295,146 295 319,396 319 Converted into common shares (a) (20,000 ) (20 ) (24,250 ) (24 ) Balance at the end of period 275,146 275 295,146 295 Common Shares Balance at beginning of the period 1,368,856 1,369 325,901 326 Shares issued to exchangeable shares 20,000 20 24,250 24 Shares issued on conversion of loans (b) 263,639 264 985,370 986 Warrants exercised - - 33,335 34 Balance at end of the period 1,652,495 1,653 1,368,856 1,369 TOTAL SHARES 1,927,641 1,928 1,664,002 1,664 a. During the three month period ended June 30, 2018, 20,000 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250 b. During the three month period ended June 30, 2018, 263,639 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss. c. On October 29, 2018, the Company completed a reverse stock split. Refer to Note 2(a) for details.	March 31, 2018 March 31, 2017 Number of shares $ Number of shares $ Exchangeable Shares: Balance beginning of year 319,396 319 333,334 333 Converted into common shares (e) (24,250 ) (24 ) (13,938 ) (14 ) Balance at end of year 295,146 295 319,396 319 Common Shares Balance at beginning of the year 325,901 326 150,608 150 Shares issued on acquisition (Note 4) - - 157,667 157 Shares issued to exchangeable shareholders (e) 24,250 24 13,938 14 Shares issued for services (d) - - 1,447 2 Shares issued on conversion of loans (b) 985,370 986 - - Options exercised (Note 11) - - 734 1 Warrants exercised (a) 33,335 33 1,165 1 Cashless exercise of warrants (c) - - 342 1 Balance at end of the year 1,368,856 1,369 325,901 326 TOTAL SHARES 1,664,002 1,664 645,297 645 (a) During the year ended March 31, 2018, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $37.50 per share, and as a result, 33,335 common shares were issued for net proceeds of $1,125,038 (Note 12). (b) During the year ended March 31, 2018, the Company converted $9,171,604 of notes payable and interest into 985,370 common shares. Under the terms of this conversion the remaining $1,220,629 of principal and interest was required to be converted into 263,639 common shares, but were unable to be issued as a result of the Company not having enough authorized shares. The $2,470,622 value of these shares at March 31, 2018 has been classified as a liability until the common shares can be issued. In addition, there was a $376,674 loss recorded in the year connected to the difference of the $2,847,296 market value of the shares at March 31, 2018 and the value of these shares which resulted on the conversion of notes payable, the exercise price of which was based on a 30 day VWAP. (c) During the year ended March 31, 2017, 342 common shares were issued as a result of a cashless exercise of 1,747 warrants with an exercise price of $120.00. Under the terms of the warrant agreement the value of the warrants on exercise is attributed to the shares on exercise and the Company has recognized a value of $43,562. (d) The Company issued 1,447 common shares during the year ended March 31, 2017 for consulting services and recognized $59,500 of share compensation expense. (e) During the year ended March 31, 2018, 24,250 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2017 – 13,938 shares) (f) On October 29, 2018, the Company completed a one-for-one hundred and fifty to one (1:150) reverse stock consolidation.

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions: Expected life Risk free Dividend Forfeiture Expected Grant date Grant date in rate rate rate volatility fair February 17, 2015 3.89 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 3.25 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 3.22 1.59 % 0 % 0 % 114 % $ 118,957 April 1, 2014 3.01 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 4.65 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 4.71 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 6.11 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 5.07 1.59 % 0 % 0 % 114 % $ 213,750 August 8, 2016 5.36 1.59 % 0 % 0 % 114 % $ 652,068 February 6, 2017 5.86 1.59 % 0 % 0 % 114 % $ 245,200 February 13, 2017 5.88 1.59 % 0 % 0 % 114 % $ 148,750 August 3, 2017 6.35 1.59 % 0 % 0 % 114 % $ 387,209 September 1, 2017 9.43 1.59 % 0 % 0 % 114 % 1,832,304 January 24, 2018 6.82 1.59 % 0 % 0 % 114 % $ 491,036
Share-based Compensation, Stock Options, Activity [Table Text Block]		Number of Options Weighted-Average Outstanding, March 31, 2017 66,024 88.50 Issued 119,036 23.25 Exercised - - Expired - - Cancelled (14,385 ) 97.50 Outstanding, March 31, 2018 170,675 75.00
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of June 30, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 24.75 1,028 April 1, 2021 1,028 34.50 630 June 20, 2021 630 34.50 13,212 July 1, 2021 13,212 34.50 944 February 17, 2022 944 183.00 2,667 November 24, 2022 1,778 150.00 12,912 December 14, 2022 10,889 142.50 747 March 28, 2023 747 157.50 2,887 March 28, 2023 2,887 150.00 1,667 April 26, 2023 1,112 150.00 1,667 August 8, 2023 1,667 105.00 2,667 February 6, 2024 889 102.00 1,667 February 13, 2024 1,667 142.50 211 March 3, 2024 211 157.50 816 March 3, 2024 816 142.50 43 March 14, 2024 43 157.50 164 March 14,2024 164 142.50 485 September 30, 2024 485 157.50 1,876 September 30, 2024 1,876 142.50 24 June 2, 2025 24 157.50 90 June 2, 2025 90 37.50 442 December 30, 2025 442 142.50 328 December 30, 2025 182 24.15 81,436 September 1, 2027 13,573 23.25 22,434 January 24, 2025 - 9.735 40,000 April 19, 2028 40,000 6.93 5,000 June 10, 2025 - 196,044 95,356	The following is a summary of stock options outstanding and exercisable as of March 31, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 24.75 1,762 April 1, 2021 1,762 34.50 651 June 20, 2021 651 34.50 13,212 July 1, 2021 13,212 34.50 944 February 17, 2022 944 183.00 2,667 November 24, 2022 1,778 150.00 13,289 December 14, 2022 11,178 142.50 747 March 28, 2023 747 157.50 2,887 March 28, 2023 2,887 150.00 1,667 April 26, 2023 556 150.00 5,000 August 8, 2023 1,667 105.00 2,667 February 6, 2024 889 102.00 1,667 February 13, 2024 1,111 142.50 211 March 3, 2024 211 157.50 816 March 3, 2024 816 142.50 43 March 14, 2024 43 157.50 164 March 14, 2024 164 142.50 485 September 30, 2024 485 157.50 1,876 September 30, 2024 1,876 142.50 23 June 2, 2025 23 157.50 90 June 2, 2025 90 37.50 442 December 30, 2025 442 142.50 328 December 30, 2025 182 31.50 13,334 August 3, 2024 - 24.15 81,436 September 1, 2027 13,573 23.25 24,267 January 24, 2025 - 170,675 55,287
Schedule of Share-based Payment Award,Reclassification of Stock Options, Valuation Assumptions [Table Text Block]		As the Company does not have sufficient authorized shares of common stock to cover its options issued, a valuation of these options was done at March 31, 2018 and the resulting liability of $1,451,393 has been recorded in the consolidated balance sheet as shares to be issued, stock options and warrants. Grant Date Expected Life Risk Free rate Dividend rate Forfeiture Rate Expected Volatility Remeasured February 17, 2015 3.89 1.59 % 0 % 0 % 135 % $ 7,122 July 1, 2014 3.25 1.59 % 0 % 0 % 135 % $ 90,472 June 20, 2014 3.22 1.59 % 0 % 0 % 135 % $ 4,428 April 1, 2014 3.01 1.59 % 0 % 0 % 135 % $ 12,437 November 24, 2015 4.65 1.59 % 0 % 0 % 135 % $ 16,327 December 14, 2015 4.71 1.59 % 0 % 0 % 135 % $ 85,833 April 21, 2016 6.39 1.59 % 0 % 0 % 118 % $ 53,853 April 26, 2016 5.07 1.59 % 0 % 0 % 114 % $ 11,430 August 8, 2016 5.36 1.59 % 0 % 0 % 114 % $ 35,722 February 6, 2017 5.86 1.59 % 0 % 0 % 114 % $ 16,969 February 13, 2017 5.88 1.59 % 0 % 0 % 114 % $ 10,703 August 3, 2017 6.35 1.59 % 0 % 0 % 114 % $ 109,970 September 1, 2017 9.43 1.59 % 0 % 0 % 114 % $ 782,966 January 24, 2018 6.82 1.59 % 0 % 0 % 114 % $ 213,161 1,451,393

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Exercise Price ($) Outstanding and exercisable, March 31, 2015 72,157 202.50 Issued 48,171 202.50 Exercised (992 ) (120.00 ) Outstanding and exercisable, March 31, 2016 119,336 202.50 Exercised (1,747 ) (120.00 ) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) 37.50 Issued in connection with anti-dilution provision connected to warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected to warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with the conversion of loans and interest into common shares 106,709 9.375 Issued in connection with the conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected to warrant transaction 136,388 73.02 Issued in connection with anti-dilution provision connected to warrant transaction 13,464 44.28 Outstanding at June 30, 2018 and March 31, 2018 365,974 53.19 * Adjusted to reflect a one-for-one hundred and fifty (1:150) reverse stock split effective October 29, 2018.	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Outstanding and exercisable, March 31, 2015 72,157 202.50 Issued 48,171 202.50 Exercised (992 ) (120.00 ) Outstanding and exercisable, March 31, 2016 119,336 202.50 Exercised (1,747 ) (120.00 ) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with conversion of loans and interest into common shares 106,709 9.375 Issued in connection with conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected with issuance of common shares 136,388 73.02 Issued in connection with anti-dilution provision connected with issuance of common shares 13,464 44.28 Outstanding and exercisable, March 31, 2018 365,974 $ 53.19
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants as of June 30, 2018: Exercise Number of Expiry Date 90.00 15,658 March 31, 2023 73.02 104,019 February 26, 2019 73.02 21,768 March 27, 2019 73.02 5,813 March 31, 2019 73.02 45,061 April 21, 2019 73.02 21,274 May 27,2019 73.02 20,782 June 30, 2019 44.28 22,223 February 26, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 365,974	The following is a summary of common share purchase warrants outstanding after the warrant offer to amend and exercise the additional warrant issue and the re-pricing of the warrants as of March 31, 2018. Exercise Price ($) Number of Warrants Expiry Date 90.00 15,658 March 31, 2023 73.02 104,019 February 26, 2019 73.02 21,768 March 27, 2019 73.02 5,813 March 31, 2019 73.02 45,061 April 21, 2019 73.02 21,274 May 27, 2019 73.02 20,782 June 30, 2019 44.28 22,223 February 26, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 365,974
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Exercise Number of Expiry Date Expected life Risk free Dividend Forfeiture Expected Remeasured 90.00 15,658 31-Mar-23 5 1.59 % 0 % 0 % 135 % 116,142 73.02 104,019 26-Feb-19 0.92 1.59 % 0 % 0 % 135 % 100,281 73.02 21,768 27-Mar-19 1 1.59 % 0 % 0 % 135 % 24,815 73.02 5,813 31-Mar-19 1 1.59 % 0 % 0 % 135 % 6,769 73.02 45,061 21-Apr-19 1.08 1.59 % 0 % 0 % 135 % 58,358 73.02 21,274 27-May-19 1.16 1.59 % 0 % 0 % 135 % 32,276 73.02 20,782 30-Jun-19 1.25 1.59 % 0 % 0 % 135 % 36,116 44.28 22,223 26-Feb-19 0.92 1.59 % 0 % 0 % 135 % 38,423 9.375 64,025 14-Aug-22 4.38 1.59 % 0 % 0 % 135 % 593,355 9.375 42,684 31-Mar-22 4 1.59 % 0 % 0 % 135 % 387,529 363,307 1,394,164

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Components of net (loss) before income taxes consists of the following: March 31 March 31 $ $ U.S. (12,281,398 ) (6,056,384 ) Canada (2,344,392 ) (2,013,018 ) (14,625,790 ) (8,069,402 ) Net (loss) for the year before recovery of income taxes (14,625,790 ) (8,069,402 ) Statutory rate 34.04 % 35 % Expected income tax (recovery) expense (4,978,619 ) (2,824,291 ) Tax rate changes and other basis adjustments 1,748,278 44,238 Stock-based compensation 524,412 350,683 Difference in Foreign Tax Rates 184,414 - Accretion 659,458 - Share premium 425,497 - Non-deductible expense 339,296 (132,076 ) Net DTA acquired - (546,122 ) Change in valuation allowance 1,097,264 3,107,568 Recovery of income taxes - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The following deferred tax assets have not been recognized. Deferred tax reflects the tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities and consisted of the following: March 31, March 31, $ $ Equipment 70,350 73,520 Share issue costs 510 1,456 SR&ED pool 690,320 464,746 Other 535,510 629,266 Non-capital losses – Canada 2,515,170 2,067,203 Net operating losses – U.S. 4,331,850 4,534,710 Valuation allowance (7,017,430 ) (5,956,118 ) 1,126,280 1,814,783 Intangibles and other (1,126,280 ) (1,814,783 ) - -
Summary of Income Tax Examinations [Table Text Block]	In many cases the Company’s uncertain tax positions are related to tax years that remain subject to examination by tax authorities. The following describes the open tax years, by major tax jurisdiction, as of March 31, 2018: United States – Federal 2014 – present United States – State 2014 – present Canada – Federal 2013 – present Canada – Provincial 2013 – present

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 21, 2016	Feb. 26, 2015	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Apr. 02, 2017	Dec. 31, 2014
Working Capital Surplus (Deficit)			$ 3,152,267		$ 6,711,941	$ 3,415,670
Comprehensive Income (Loss), Net of Tax, Attributable to Parent			$ (760,698)	$ (2,240,518)	$ (14,625,790)	$ (8,069,402)
Common Stock, Shares Authorized			500,000,000		250,000,000	150,000,000		200,000,000
Retained Earnings (Accumulated Deficit)			$ (36,537,038)		$ (35,776,340)	$ (21,076,464)	$ (21,076,464)
Stockholders' Equity, Reverse Stock Split					Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock split of the common and exchangeable shares.
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	157,667
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues		333,334
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

BASIS OF PRESENTATION AND CHA_3

BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales	$ 501,333	$ 87,520	$ 987,431	$ 571,945
Cost of Sales	253,163	29,300	402,665	388,756
Total operating expenses	2,882,941	2,127,589	10,354,032	8,829,481
Total other expenses	(1,874,073)	171,149	4,856,524	(576,890)
Net loss and comprehensive loss for the period	$ (760,698)	$ (2,240,518)	$ (14,625,790)	$ (8,069,402)
Loss per share – basic	$ (0.44)	$ (3.47)		$ (13.19)
Diluted loss per share	$ (0.44)	$ (3.47)		$ (13.19)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales		$ 87,520		$ 571,945
Cost of Sales		29,300		388,756
Total operating expenses		2,127,589		8,829,481
Total other expenses		175,953		(4,709,718)
Net loss and comprehensive loss for the period		(2,245,322)		$ (3,936,574)
Loss per share – basic				$ (6)
Diluted loss per share				$ (6)
Scenario, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales		0		$ 0
Cost of Sales		0		0
Total operating expenses		0		0
Total other expenses		(4,804)		4,132,828
Net loss and comprehensive loss for the period		$ 4,804		$ (4,132,828)
Loss per share – basic				$ (7.50)
Diluted loss per share				$ (7.50)

BASIS OF PRESENTATION AND CHA_4

BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY (Details 1) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss for period	$ (760,698)	$ (2,240,518)	$ (14,625,790)	$ (8,069,402)
Adjustment for items not affecting cash and changes in non-cash working capital items		933,861		1,077,089
Net cash used in operating activities	(2,421,086)	(1,306,657)	(7,710,862)	(6,992,313)
Net cash used in investing activities	(7,844)	(15,600)	(21,567)	(170,790)
Net cash provided by financing activities	2,881,323	1,625,038	7,696,090	2,324,996
Net increase in cash and cash equivalents for the period	452,393	302,781	(36,339)	(4,838,107)
Cash and cash equivalents, beginning of period	507,311	543,650	543,650	5,381,757
Cash and cash equivalents, end of period	$ 959,704	846,431	507,311	543,650
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss for period		(2,245,322)		(3,936,574)
Adjustment for items not affecting cash and changes in non-cash working capital items		938,665		(3,055,739)
Net cash used in operating activities		(1,306,657)		(6,992,313)
Net cash used in investing activities		(15,600)		(170,790)
Net cash provided by financing activities		1,625,038		2,324,996
Net increase in cash and cash equivalents for the period		302,781		(4,838,107)
Cash and cash equivalents, beginning of period		543,650	543,650	5,381,757
Cash and cash equivalents, end of period		846,431		543,650
Scenario, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss for period		4,804		(4,132,828)
Adjustment for items not affecting cash and changes in non-cash working capital items		(4,804)		4,132,828
Net cash used in operating activities		0		0
Net cash used in investing activities		0		0
Net cash provided by financing activities		0		0
Net increase in cash and cash equivalents for the period		0		0
Cash and cash equivalents, beginning of period		0	$ 0	0
Cash and cash equivalents, end of period		$ 0		$ 0

BASIS OF PRESENTATION AND CHA_5

BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY (Details 2) - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Apr. 02, 2017	Mar. 31, 2017	Mar. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current assets	$ 1,989,664	$ 1,410,036		$ 1,402,580	$ 1,402,580
Capital assets	150,210	159,961		227,421	227,421
Intangible assets				27,338,899
Total assets	29,083,815	28,584,991		28,968,900	28,968,900
Warrant derivative liability				0
Other current liabilities	5,141,931	8,121,977		4,818,250	4,818,250
Total liabilities				4,818,250
Common stock	1,928	1,664		645	645
Additional paid in capital	60,434,845	56,195,541		45,184,320	45,184,320
Deficit	(36,537,038)	(35,776,340)		(21,076,464)	(21,076,464)
Accumulated other comprehensive income	42,149	42,149		42,149	42,149
Total shareholders' equity	23,941,884	20,463,014	$ 23,491,008	24,150,650	24,150,650	$ 5,399,851
Total liabilities and shareholders' equity	$ 29,083,815	$ 28,584,991		28,968,900	28,968,900
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current assets					1,402,580
Capital assets					227,421
Intangible assets					27,338,899
Total assets					28,968,900
Warrant derivative liability					959,600
Other current liabilities					4,818,205
Total liabilities					5,777,805
Common stock					645
Additional paid in capital					38,736,855
Deficit					(15,588,554)
Accumulated other comprehensive income					42,149
Total shareholders' equity					23,191,095
Total liabilities and shareholders' equity					$ 28,968,900
Scenario, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current assets				0
Capital assets				0
Intangible assets				0
Total assets				0
Warrant derivative liability				(959,600)
Other current liabilities				45
Total liabilities				(959,555)
Common stock				0
Additional paid in capital				6,447,465
Deficit				(5,487,910)
Accumulated other comprehensive income				0
Total shareholders' equity				959,555
Total liabilities and shareholders' equity				$ 0

BASIS OF PRESENTATION AND CHA_6

BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 29, 2018	Mar. 31, 2018	Jun. 30, 2018	Apr. 02, 2017	Mar. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings (Accumulated Deficit)		$ (35,776,340)	$ (36,537,038)	$ (21,076,464)	$ (21,076,464)
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001		$ 0.001
Stockholders' Equity, Reverse Stock Split		Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock split of the common and exchangeable shares.
Scenario, Forecast [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity, Reverse Stock Split	On October 29, 2018, the Company effected the reverse stock split and thereafter the Company's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings (Accumulated Deficit)					$ (15,588,554)

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 75,065		$ 64,957	$ 64,957
Product Warranty Expense	$ 10,108	$ 0		$ 0
Disclosure on Geographic Areas, Long-Lived Assets			Approximately 99% of the Company’s assets are US-based and all sales for the years ended March 31, 2018 and 2017 were made by the Company’s US subsidiary, Bionik, Inc. In addition, all of the Company’s technology and other assets and goodwill are connected to the acquisition by the Company in April 2016 of Bionik, Inc. Equipment connected to Bionik Inc. amounts to $120,910 and $39,051 is connected to equipment at the Company’s Canadian subsidiary Bionik Laboratories Inc.
Common Stock, Shares Authorized	500,000,000		250,000,000	150,000,000	200,000,000
(Gain) loss on market to market revaluation	$ (2,048,697)	$ 0	$ 376,674	$ 0
Computer And Electronics [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			50.00%
Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			20.00%
Demonstration Equipment [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			50.00%
Manufacturing Equipment [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			20.00%
Tool and Parts [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			20.00%
Equipment [Member] | CANADA
Significant Accounting Policies [Line Items]
Equipment, Net			$ 39,051
Equipment [Member] | UNITED STATES
Significant Accounting Policies [Line Items]
Equipment, Net			$ 120,910

ACQUISITION, TECHNOLOGY AND O_3

ACQUISITION, TECHNOLOGY AND OTHER ASSETS (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 21, 2016	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Amortization of Intangible Assets		$ 71,053	$ 92,949	$ 323,905	$ 550,080
Intangible Assets, Net (Excluding Goodwill)		4,635,666		4,706,719	5,030,624
Patents and exclusive License Agreement [Member]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031
Amortization of Intangible Assets		33,522		134,126	126,375
Intangible Assets, Net (Excluding Goodwill)		1,012,008		1,045,530	1,179,656
Trademark [Member]
Finite Lived Intangible Asset Useful Life Description	Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 2,505,907
Amortization of Intangible Assets		0		0	0
Intangible Assets, Net (Excluding Goodwill)		2,505,907		2,505,907	2,505,907
Customer relationships [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680
Amortization of Intangible Assets		35,792		143,206	134,931
Intangible Assets, Net (Excluding Goodwill)		1,117,751		1,153,543	1,296,749
Non - compete agreement [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366
Amortization of Intangible Assets		1,739		30,709	28,918
Intangible Assets, Net (Excluding Goodwill)		0		1,739	32,448
Assembled Workforce [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets		0		15,864	259,856
Intangible Assets, Net (Excluding Goodwill)		$ 0		$ 0	$ 15,864

ACQUISITION, TECHNOLOGY AND O_4

ACQUISITION, TECHNOLOGY AND OTHER ASSETS (Details 1) - USD ($)		1 Months Ended
		Apr. 21, 2016	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition [Line Items]
Fair value of 23,650,000 shares of common stock	[1]	$ 23,177,000
Fair value of vested stock options	[2]	2,582,890
Allocation of purchase price:		25,759,890
Cash and cash equivalents		266,635
Accounts receivable		6,490
Inventories		188,879
Prepaid expenses and other current assets		16,839
Equipment		59,749
Liabilities assumed:
Accounts payable		(241,299)
Accrued liabilities		(361,029)
Customer deposits		(86,487)
Demand notes payable		(324,894)
Promissory notes payable		(217,808)
Bionik advance	[3]	(1,436,164)
Net assets acquired		(2,129,089)
Goodwill		22,308,275	$ 22,308,275	$ 22,308,275	$ 22,308,275
Total Allocation of purchase price		25,759,890
Patents and exclusive License Agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,306,031
Customer Relationships [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,431,680
Non compete agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		61,366
Assembled Workforce [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		275,720
Trademarks [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 2,505,907
[1]	The fair value of common stock was based on $147.00 per share, which was the closing market price of the Company’s common stock on April 21, 2016.
[2]	The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 11).
[3]	Included in the net assets acquired was a loan issued to IMT in the amount of $300,000 under normal commercial terms. The loan carried an interest rate of 6% and were secured by all the assets of IMT subject to a $200,000 subordination to a third party financial services company, which was released in April 2016.

ACQUISITION, TECHNOLOGY AND O_5

ACQUISITION, TECHNOLOGY AND OTHER ASSETS (Details 2) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 21, 2016	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition [Line Items]
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Amortization of Intangible Assets		$ 71,053	$ 92,949	$ 323,905	$ 550,080
Intangible Assets, Net (Excluding Goodwill)		4,635,666		4,706,719	5,030,624
Patents and exclusive License Agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031
Amortization of Intangible Assets		33,522		134,126	126,375
Intangible Assets, Net (Excluding Goodwill)		1,012,008		1,045,530	1,179,656
Trademark [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 2,505,907
Amortization of Intangible Assets		0		0	0
Intangible Assets, Net (Excluding Goodwill)		2,505,907		2,505,907	2,505,907
Customer relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680
Amortization of Intangible Assets		35,792		143,206	134,931
Intangible Assets, Net (Excluding Goodwill)		1,117,751		1,153,543	1,296,749
Non compete agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366
Amortization of Intangible Assets		1,739		30,709	28,918
Intangible Assets, Net (Excluding Goodwill)		0		1,739	32,448
Assembled Workforce [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets		0		15,864	259,856
Intangible Assets, Net (Excluding Goodwill)		$ 0		$ 0	$ 15,864

ACQUISITION, TECHNOLOGY AND O_6

ACQUISITION, TECHNOLOGY AND OTHER ASSETS (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 21, 2016	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		196,044		170,675
Fair Value Assumption Risk Free Interest Rate	1.59%			1.91%
Fair Value Assumption Forfeited rate	0.00%
Fair Value Assumption Expected Volatility Rate	114.00%
Debt Instrument, Interest Rate, Stated Percentage						1.50%
Amortization of Intangible Assets		$ 71,053	$ 92,949	$ 323,905	$ 550,080
Exercise Price 37.50 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 37.50
Exercise Price 142.50 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 142.50
Exercise Price 157.50 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,666
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 157.50
Interactive Motion Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Acquisition, Effective Date of Acquisition	Apr. 21, 2016
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	157,667
Business Acquisition, Number Of Option Acquired	3,895,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	20,000
Allocated Share-based Compensation Expense	$ 2,582,890
Share Price	$ 147
Loans and Leases Receivable, Related Parties	$ 300,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Subordinated Debt	$ 200,000

PREPAID EXPENSES AND OTHER RE_3

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables		$ 73,987	$ 86,957	$ 68,484
Prepaid inventory		261,626	301,104	0
Prepaid insurance		136,113	36,497	136,896
Sales taxes receivable	[1]	13,712	9,097	22,667
Prepaid Expense and Other Receivables		$ 485,438	$ 433,655	$ 228,047
[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Inventory [Line Items]
Raw materials	$ 124,795	$ 237,443	$ 119,985
Work in Progress	31,000	0	108,264
Inventory, Net	$ 155,795	$ 237,443	$ 228,249

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Inventory Write-down			$ 38,860	$ 43,009
Cost of Goods and Services Sold	$ 253,163	$ 29,300	$ 402,665	388,756
Inventory Cost [Member]
Cost of Goods and Services Sold	$ 237,000	$ 29,300
InMotion Products [Member]
Inventory Write-down				$ 124,416

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Apr. 02, 2017	Mar. 31, 2017
Equipment [Line Items]
Equipment, Cost	$ 624,513	$ 616,669		$ 595,102
Accumulated Depreciation	474,303	456,708		367,681
Equipment, Net	150,210	159,961	$ 227,421	227,421
Computers and electronics [Member]
Equipment [Line Items]
Equipment, Cost	264,349	256,505		250,538
Accumulated Depreciation	227,977	223,750		204,258
Equipment, Net	36,372	32,755		46,280
Furniture and fixtures [Member]
Equipment [Line Items]
Equipment, Cost	36,795	36,795		36,795
Accumulated Depreciation	28,481	28,051		26,096
Equipment, Net	8,314	8,744		10,699
Demonstration equipment [Member]
Equipment [Line Items]
Equipment, Cost	200,186	200,186		184,586
Accumulated Depreciation	116,798	105,441		44,420
Equipment, Net	83,388	94,745		140,166
Manufacturing equipment [Member]
Equipment [Line Items]
Equipment, Cost	88,742	88,742		88,742
Accumulated Depreciation	85,819	85,668		84,982
Equipment, Net	2,923	3,074		3,760
Tools and parts [Member]
Equipment [Line Items]
Equipment, Cost	11,422	11,422		11,422
Accumulated Depreciation	6,020	5,741		4,472
Equipment, Net	5,402	5,681		6,950
Assets under capital lease [Member]
Equipment [Line Items]
Equipment, Cost	23,019	23,019		23,019
Accumulated Depreciation	9,208	8,057		3,453
Equipment, Net	$ 13,811	$ 14,962		$ 19,566

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Equipment [Line Items]
Depreciation	$ 17,595	$ 24,552	$ 89,026	$ 79,868

NOTES PAYABLE Demand Notes pa_3

NOTES PAYABLE Demand Notes payable (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Repayment of principal	$ 50,000	$ 0	$ 208,359	$ 0
Repayment of interest	2,975	0	79,259	0
Repayment			200,000	0
Demand Notes payable [Member]
Balance	51,479	$ 330,600	330,600	0
Acquisition of IMT (Note 4)				324,894
Accrued Interest	1,496		8,497	5,706
Repayment of principal			(208,359)
Repayment of interest			(79,259)
Repayment	52,975
Balance	$ 0		$ 51,479	$ 330,600

NOTES PAYABLE Demand Notes pa_4

NOTES PAYABLE Demand Notes payable (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Repayment of interest	$ 49,505	$ 0
Promissory Note [Member]
Balance	236,548	0
Acquisition of IMT		217,808
Accrued Interest	12,957	18,740
Repayment of principal	(200,000)
Repayment of interest	(49,505)
Balance	$ 0	$ 236,548

NOTES PAYABLE Demand Notes pa_5

NOTES PAYABLE Demand Notes payable (Details 2) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Jan. 15, 2017	Dec. 31, 2016
Principal			$ 0	$ 2,000,000	$ 500,000	$ 500,000
Accretion expense	$ 134,251	$ 0	$ 1,937,308	$ 0
Convertible Debt [Member]
Principal	2,965,971
Beneficial conversion	368,936
Anti-dilution	1,042,632
Fair value of Debt	1,554,403
Accretion expense	134,251
Interest	3,533
Convertible Notes Payable, Noncurrent	$ 1,692,187

NOTES PAYABLE Demand Notes pa_6

NOTES PAYABLE Demand Notes payable (Details 3) - Convertible Debt [Member]	3 Months Ended
	Jun. 30, 2018USD ($)
At Issuance	$ 1,411,568
Fair value adjustment	44,087
Ending balance at June 30, 2018	1,455,655
Beneficial conversion [Member]
At Issuance	368,936
Fair value adjustment	60,304
Ending balance at June 30, 2018	429,240
Antidilution [Member]
At Issuance	1,042,632
Fair value adjustment	(16,217)
Ending balance at June 30, 2018	$ 1,026,415

NOTES PAYABLE Demand Notes pa_7

NOTES PAYABLE Demand Notes payable (Details 4) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Accretion expense	$ 134,251	$ 0	$ 1,937,308	$ 0
Convertible Debt [Member]
Balance	$ 0	$ 2,017,488	2,017,488	0
Additional principal investment			2,999,975	2,000,000
Fair value of warrants			(548,178)
Accretion expense			548,178
Accrued Interest			1,037,067	17,488
Conversion of principal and interest			(6,054,530)
Balance			$ 0	$ 2,017,488

NOTES PAYABLE Demand Notes pa_8

NOTES PAYABLE Demand Notes payable (Details 5) - Convertible Debt One [Member]	12 Months Ended
	Mar. 31, 2018USD ($)
Balance	$ 0
Additional principal investment	500,000
Accrued Interest	33,556
Conversion of principal and interest	(533,556)
Balance	$ 0

NOTES PAYABLE Demand Notes pa_9

NOTES PAYABLE Demand Notes payable (Details 6) - Convertible Debt Two [Member]	12 Months Ended
	Mar. 31, 2018USD ($)
Balance	$ 0
Additional principal investment	3,611,400
Accrued Interest	201,928
Conversion of principal and interest	(3,813,328)
Balance	$ 0

NOTES PAYABLE Demand Notes p_10

NOTES PAYABLE Demand Notes payable (Details 7) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Premium	$ 1,249,994	$ 0
Convertible Notes Payable (December 2016 to December 2017) [Member] | Joint Venture Partner [Member]
Principal	4,999,975
Interest	1,054,555
Premium	1,249,994
Total Conversion Amount	7,304,523
Beneficial Conversion Feature	$ 762,301
Number of Shares Converted	779,461
Chinese Convertible Loan [Member] | Joint Venture Partner [Member]
Principal	$ 500,000
Interest	33,556
Premium	0
Total Conversion Amount	533,556
Beneficial Conversion Feature	$ 76,230
Number of Shares Converted	62,629
Convertible Notes Payable (December 2017 to March 2018) [Member] | Joint Venture Partner [Member]
Principal	$ 3,611,400
Interest	201,928
Premium	0
Total Conversion Amount	3,813,328
Beneficial Conversion Feature	$ 550,598
Number of Shares Converted	406,918
Convertible Notes Payable [Member]
Principal	$ 9,111,375
Interest	1,290,039
Premium	1,249,994
Total Conversion Amount	11,651,407
Beneficial Conversion Feature	$ 1,389,129
Number of Shares Converted	1,249,008

NOTES PAYABLE Demand Notes p_11

NOTES PAYABLE Demand Notes payable (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Jan. 31, 2018

Dec. 31, 2017

Feb. 14, 2017

Apr. 21, 2016

Jun. 30, 2018

Jun. 30, 2017

Mar. 31, 2018

Mar. 31, 2017

Jul. 20, 2018

Jan. 15, 2017

Dec. 31, 2016

Mar. 31, 2016

Feb. 28, 2014

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

Debt Instrument, Face Amount

$ 0

$ 2,000,000

$ 500,000

$ 500,000

Debt Instrument, Convertible, Terms of Conversion Feature

On the maturity date, without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the notes will be converted into shares of new round stock based upon a 15% discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the qualified financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a qualified financing) in the event of a maturity date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the maturity date in the event of a maturity date referred to in clause (a) of the definition thereof, and (ii) $0.18.

Short-term Debt

$ 0

$ 51,479

330,600

Proceeds from Related Party Debt

$ 400,000

2,291,930

Interest Expense, Related Party

0

Repayments of Related Party Debt

$ 3,200

3,200

Due to Officers or Stockholders

4,999,975

Warrants Not Settleable in Cash, Fair Value Disclosure

$ 1,037,067

Fair Value Assumption Expected Volatility Rate

114.00%

Fair Value Assumption Risk Free Interest Rate

1.59%

1.91%

Debt Instrument, Interest Rate Terms

In December 2017, investors of the Company advanced funds under a new convertible loan offering. These convertible loans bear interest at a fixed rate of 3% per month until the earlier of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than $7,000,000 and up to $14,000,000 raised in one or more tranches.

In December 2017, investors of the Company advanced funds under a new convertible loan offering. These convertible loans bear interest at a fixed rate of 3% per month until the earlier of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than $7,000,000 and up to $14,000,000 raised in one or more tranches.

Proceeds from Convertible Debt

2,934,298

$ 500,000

$ 7,111,375

2,000,000

Discount on Convertible Loans

10.00%

Interest Costs Capitalized

31,673

Accretion Expense

$ 134,251

0

$ 1,937,308

$ 0

Debt Conversion, Converted Instrument, Type

On the maturity date, without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the notes will be converted into shares of new round stock based upon a 15% discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the qualified financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a qualified financing) in the event of a maturity date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the maturity date in the event of a maturity date referred to in clause (a) of the definition thereof, and (ii) $0.18.

Amendment Of Convertible Loan Agreement Description

In January 2018, the terms of the new convertible loan offering were amended to extend the maturity date until March 31, 2018 and in March 2018 the terms of the loans were amended to change the definition of qualified financing as gross proceeds of no less than $2,000,000 and up to $14,000,000 raised in one or more tranches.

Debt Conversion, Original Debt, Amount

$ 50,000

Debt Conversion, Original Debt, Interest Rate of Debt

6.00%

Portion Of Debt Instrument ConvertedDescription

Further, the Company issued warrants to these debt holders amounting to 20% of the aggregate principal of the convertible loans divided by the exercise price, which would be determined as the lowest of a new round stock in a qualified financing, the average volume weighted average price for the sixty trading days prior to January 31, 2018 or $0.25.

Fair Value Assumptions Term

5 years

Warrant [Member]

Debt Instrument [Line Items]

Fair Value Measurement Valuation Techniques

binomial valuation model

Fair Value Assumption Exercise Price

$ 0.25

Fair Value Assumption Expected Volatility Rate

114.00%

Convertible Debt [Member]

Debt Instrument [Line Items]

Interest Expense, Debt

$ 1,037,067

$ 17,488

Debt Instrument, Face Amount

$ 1,500,000

Interest Payable, Current

$ 17,488

Debt Instrument, Convertible, Terms of Conversion Feature

upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of $7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to 25% of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) $0.25.

The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000

Proceeds from Contributions from Affiliates

$ 2,999,975

2,000,000

Accretion Expense

548,178

Convertible Loans Payable [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.00%

Interest Expense, Debt

201,928

Proceeds from Contributions from Affiliates

3,611,400

Accretion Expense

$ 134,251

0

Debt Instrument Convertible Conversion feature Fair Value Adjustments

44,087

0

Convertible Debt One [Member]

Debt Instrument [Line Items]

Interest Expense, Debt

33,556

Proceeds from Contributions from Affiliates

500,000

Debt Instrument, Interest Rate Terms

In January 2018, the terms of the new convertible loan offering were amended to extend the maturity date until March 31, 2018 and in March 2018 the terms of the loans were amended to change the definition of qualified financing as gross proceeds of no less than $2,000,000 and up to $14,000,000 raised in one or more tranches.

Fourth Tranches [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

500,000

IMT Notes [Member]

Debt Instrument [Line Items]

Interest Expense, Debt

$ 2,341

8,497

5,706

Promissory Note [Member]

Debt Instrument [Line Items]

Notes Payable

$ 200,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Interest Expense, Debt

12,957

18,740

Demand Notes payable [Member]

Debt Instrument [Line Items]

Notes Payable

0

51,479

330,600

$ 0

Interest Expense, Debt

$ 1,496

$ 8,497

$ 5,706

Joint Venture Partner [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

the Company’s Chinese joint venture partners loaned the Company $500,000 at an interest rate of 8% convertible into the Company’s common shares upon a capital raise (“Qualified Financing”) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on the conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion.

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Related Party Transaction [Line Items]
Accrued interest receivable	$ 59	$ 590	$ 707
Royalty on Sales, Percentage	1.00%	1.00%
Related Party Transaction, Rate	1.00%	1.00%
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	$ 18,547	$ 18,897	18,731
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,957	208,567	0
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,643	135,039	0
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 920	116,624	0
Chief Commercial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties		$ 600	97,500
Interactive Motion Technologies, Inc. [Member] | Director [Member]
Related Party Transaction [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		34,603
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		2,402
Former Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties		$ 587,019	$ 4,135

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		3 Months Ended			9 Months Ended	12 Months Ended
		Jun. 30, 2018		Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2018		Mar. 31, 2017
Opening Balance		$ 20,463,014		$ 24,150,650	$ 23,491,008	$ 24,150,650		$ 5,399,851
Shares issued on acquisition (Note 4)								23,177,000
Shares issued to exchangeable shares		2,470,622			9,180,785	9,180,785
Options exercised (Note 11)								18,166
Warrants exercised				1,125,038		1,125,038		40,195
Cashless exercise of warrants (iv)								0
Closing Balance		$ 23,941,884		$ 23,491,008	$ 20,463,014	$ 20,463,014		$ 24,150,650
Exchangeable Shares [Member]
Opening Balance (in shares)		295,146		319,396		319,396
Opening Balance		$ 295		$ 319		$ 319
Converted into common shares (in shares)		(20,000)	[1]			(24,250)	[1]	(13,938)	[2]
Converted into common shares		$ (20)	[1]			$ (24)	[1]	$ (14)	[2]
Shares issued to exchangeable shares (in shares)	[2]							13,938
Shares issued to exchangeable shares	[2]							$ 14
Closing Balance (in shares)		275,146			295,146	295,146		319,396
Closing Balance		$ 275			$ 295	$ 295		$ 319
Common Shares [Member]
Opening Balance (in shares)		1,368,856		325,901		325,901		150,608
Opening Balance		$ 1,369		$ 326		$ 326		$ 150
Shares issued on acquisition (Note 4) (in shares)						0		157,667
Shares issued on acquisition (Note 4)						$ 0		$ 157
Shares issued to exchangeable shares (in shares)		20,000				24,250	[2]
Shares issued to exchangeable shares		$ 20				$ 24	[2]
Shares issued for services (in shares)	[3]					0		1,447
Shares issued for services	[3]					$ 0		$ 2
Shares issued on conversion of loans (in shares)		263,639	[4]			985,370	[4]	0	[5]
Shares issued on conversion of loans		$ 264	[4]			$ 986	[4]	$ 0	[5]
Options exercised (Note 11) (in shares)						0		734
Options exercised (Note 11)						$ 0		$ 1
Warrants exercised (in shares)		0				33,335	[6]	1,165	[6]
Warrants exercised		$ 0				$ 34	[6]	$ 1	[6]
Cashless exercise of warrants (iv) (in shares)	[7]					0		342
Cashless exercise of warrants (iv)	[7]					$ 0		$ 1
Closing Balance (in shares)		1,652,495			1,368,856	1,368,856		325,901
Closing Balance		$ 1,653			$ 1,369	$ 1,369		$ 326
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)		1,664,002		319,396		319,396		333,334
Opening Balance		$ 1,664		$ 319		$ 319		$ 333
Closing Balance (in shares)		1,927,641			1,664,002	1,664,002		319,396
Closing Balance		$ 1,928			$ 1,664	$ 1,664		$ 319
[1]	During the three month period ended June 30, 2018, 20,000 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250 shares).
[2]	During the year ended March 31, 2018, 24,250 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2017 –13,938 shares)
[3]	The Company issued 1,447 common shares during the year ended March 31, 2017 for consulting services and recognized $59,500 of share compensation expense.
[4]	During the three month period ended June 30, 2018, 263,639 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss.
[5]	During the year ended March 31, 2018, the Company converted $9,171,604 of notes payable and interest into 985,370 common shares. Under the terms of this conversion the remaining $1,220,629 of principal and interest was required to be converted into 263,639 common shares, but were unable to be issued as a result of the Company not having enough authorized shares. The$2,470,622 value of these shares at March 31, 2018 has been classified as a liability until the common shares can be issued. In addition, there was a $376,674 loss recorded in the year connected to the difference of the $2,847,296 market value of the shares at March 31, 2018 and the value of these shares which resulted on the conversion of notes payable, the exercise price of which was based on a 30 day VWAP.
[6]	During the year ended March 31, 2018, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $37.50 per share, and as a result, 33,335 common shares were issued for net proceeds of $1,125,038 (Note 12).
[7]	During the year ended March 31, 2017, 342 common shares were issued as a result of a cashless exercise of 1,747 warrants with an exercise price of $120.00. Under the terms of the warrant agreement the value of the warrants on exercise is attributed to the shares on exercise and the Company has recognized a value of $43,562.

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Oct. 29, 2018	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014
Share-based Compensation		$ 595,412	$ 251,048		$ 1,540,580	$ 1,001,950
Proceeds from Warrant Exercises		$ 0	1,125,038		1,125,038	$ 40,195
Debt Conversion, Original Debt to be Converted, Amount				$ 1,220,629	$ 1,220,629
Debt Conversion, Converted Instrument, Shares to be Issued		263,639		263,639	263,639
Debt Conversion, Converted Instrument, Value of Shares to be Issued				$ 2,470,622	$ 2,470,622
Market Value of Shares				$ 2,847,296	$ 2,847,296
Stock Issued During Period, Shares, Exchangeable Shares Excercised		20,000			24,250	13,938
Common Stock, Shares Authorized		500,000,000		250,000,000	250,000,000	150,000,000	200,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities		$ 2,470,622		$ 9,180,785	$ 9,180,785
Adjustments to Additional Paid in Capital, Stock Option and Warrant Reclassification		$ 1,173,534		$ (2,845,557)	(2,845,557)
Preferred Stock, Voting Rights		the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share
(Gain) loss on market to market revaluation		$ (2,048,697)	$ 0		$ 376,674	$ 0
Stockholders' Equity, Reverse Stock Split					Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock split of the common and exchangeable shares.
Scenario, Forecast [Member]
Stockholders' Equity, Reverse Stock Split	On October 29, 2018, the Company effected the reverse stock split and thereafter the Company's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.
Common Shares [Member]
Share-based Compensation						$ 43,562
Stock Issued During Period, Shares, Conversion of Convertible Securities					985,370
Stock Issued During Period, Value, Conversion of Convertible Securities					$ 9,171,604
Investor Relation And Consultine Services [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 120
Number Of Warrants Exercised						1,747
Stock Issued During Period, Shares, Conversion of Convertible Securities						342
Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services						1,447
Stock Issued During Period, Value, Issued for Services						$ 59,500
Stock Issued During Period, Shares, Warrants Exercised			33,335		33,335	1,165
Stock Issued During Period, Shares, Conversion of Convertible Securities		263,639		985,370	985,370
Stock Issued During Period, Value, Conversion of Convertible Securities		$ 264		$ 985	$ 985
Adjustments to Additional Paid in Capital, Stock Option and Warrant Reclassification		$ 0		$ 0	$ 0
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 37.50	$ 37.50
Stock Issued During Period, Shares, Warrants Exercised					33,335
Proceeds from Warrant Exercises					$ 1,125,038

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	196,044	170,675
Number of Exercisable Options	95,356	55,287
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 24.75	$ 24.75
Number of Options	1,028	1,762
Expiry Date	Apr. 1, 2021	Apr. 1, 2021
Number of Exercisable Options	1,028	1,762
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 34.50	$ 34.50
Number of Options	630	651
Expiry Date	Jun. 20, 2021	Jun. 20, 2021
Number of Exercisable Options	630	651
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 34.50	$ 34.50
Number of Options	13,212	13,212
Expiry Date	Jul. 1, 2021	Jul. 1, 2021
Number of Exercisable Options	13,212	13,212
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 34.50	$ 34.50
Number of Options	944	944
Expiry Date	Feb. 17, 2022	Feb. 17, 2022
Number of Exercisable Options	944	944
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 183	$ 183
Number of Options	2,667	2,667
Expiry Date	Nov. 24, 2022	Nov. 24, 2022
Number of Exercisable Options	1,778	1,778
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 150	$ 150
Number of Options	12,912	13,289
Expiry Date	Dec. 14, 2022	Dec. 14, 2022
Number of Exercisable Options	10,889	11,178
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 142.50	$ 142.50
Number of Options	747	747
Expiry Date	Mar. 28, 2023	Mar. 28, 2023
Number of Exercisable Options	747	747
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 157.50	$ 157.50
Number of Options	2,887	2,887
Expiry Date	Mar. 28, 2023	Mar. 28, 2023
Number of Exercisable Options	2,887	2,887
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 150	$ 150
Number of Options	1,667	1,667
Expiry Date	Apr. 26, 2023	Apr. 26, 2023
Number of Exercisable Options	1,112	556
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 150	$ 150
Number of Options	1,667	5,000
Expiry Date	Aug. 8, 2023	Aug. 8, 2023
Number of Exercisable Options	1,667	1,667
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 105	$ 105
Number of Options	2,667	2,667
Expiry Date	Feb. 6, 2024	Feb. 6, 2024
Number of Exercisable Options	889	889
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 102	$ 102
Number of Options	1,667	1,667
Expiry Date	Feb. 13, 2024	Feb. 13, 2024
Number of Exercisable Options	1,667	1,111
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 142.50	$ 142.50
Number of Options	211	211
Expiry Date	Mar. 3, 2024	Mar. 3, 2024
Number of Exercisable Options	211	211
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 157.50	$ 157.50
Number of Options	816	816
Expiry Date	Mar. 3, 2024	Mar. 3, 2024
Number of Exercisable Options	816	816
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 142.50	$ 142.50
Number of Options	43	43
Expiry Date	Mar. 14, 2024	Mar. 14, 2024
Number of Exercisable Options	43	43
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 157.50	$ 157.50
Number of Options	164	164
Expiry Date	Mar. 14, 2024	Mar. 14, 2024
Number of Exercisable Options	164	164
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 142.50	$ 142.50
Number of Options	485	485
Expiry Date	Sep. 30, 2024	Sep. 30, 2024
Number of Exercisable Options	485	485
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 157.50	$ 157.50
Number of Options	1,876	1,876
Expiry Date	Sep. 30, 2024	Sep. 30, 2024
Number of Exercisable Options	1,876	1,876
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 142.50	$ 142.50
Number of Options	24	23
Expiry Date	Jun. 2, 2025	Jun. 2, 2025
Number of Exercisable Options	24	23
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 157.50	$ 157.50
Number of Options	90	90
Expiry Date	Jun. 2, 2025	Jun. 2, 2025
Number of Exercisable Options	90	90
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 37.50	$ 37.50
Number of Options	442	442
Expiry Date	Dec. 30, 2025	Dec. 30, 2025
Number of Exercisable Options	442	442
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 142.50	$ 142.50
Number of Options	328	328
Expiry Date	Dec. 30, 2025	Dec. 30, 2025
Number of Exercisable Options	182	182
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 24.15	$ 24.15
Number of Options	81,436	81,436
Expiry Date	Sep. 1, 2027	Sep. 1, 2027
Number of Exercisable Options	13,573	13,573
Stock Option Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 23.25	$ 23.25
Number of Options	22,434	24,267
Expiry Date	Jan. 24, 2025	Jan. 24, 2025
Number of Exercisable Options	0	0
Stock Option Twenty Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 9.735
Number of Options	40,000
Expiry Date	Apr. 19, 2028
Number of Exercisable Options	40,000
Stock Option Twenty Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.93
Number of Options	5,000
Expiry Date	Jun. 10, 2025
Number of Exercisable Options	0
Stock Option Twenty Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price		$ 31.50
Number of Options		13,334
Expiry Date		Aug. 3, 2024
Number of Exercisable Options		0

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) - Employee Stock Option [Member]	12 Months Ended
	Mar. 31, 2018USD ($)
February 17, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 10 months 20 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 136,613
July 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 3 months
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,259,487
June 20, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 2 months 19 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 118,957
November 24 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 7 months 24 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 694,384
December 14, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 8 months 16 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,260,437
April 21, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 1 month 10 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 2,582,890
April 26, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 25 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 213,750
August 8, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 4 months 10 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 652,068
February 6, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 10 months 10 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 245,200
February 13, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 10 months 17 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 148,750
April 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 4 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 230,930
August 3, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 4 months 6 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 387,209
September 1, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	9 years 5 months 5 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,832,304
January 24, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 9 months 25 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 491,036

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2)	12 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding, Ending Balance (in shares)	170,675
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Options, Outstanding, Beginning Balance (in shares)	66,024
Number of Options, Issued (in shares)	119,036
Number of Options, Exercised (in shares)	0
Number of Options, Expired (in shares)	0
Number of Options, Cancelled (in shares)	(14,385)
Number of Options, Outstanding, Ending Balance (in shares)	170,675
Weighted-Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) | $ / shares	$ 88.50
Weighted-Average Exercise Price, Issued (in dollars per share) | $ / shares	23.25
Weighted-Average Exercise Price, Exercised (in dollars per share) | $ / shares	0
Weighted-Average Exercise Price, Expired (in dollars per share) | $ / shares	0
Weighted-Average Exercise Price, Cancelled (in dollars per share) | $ / shares	97.50
Weighted-Average Exercise Price, Outstanding, Ending Balance (in dollars per share) | $ / shares	$ 75

STOCK OPTIONS (Details 3)

STOCK OPTIONS (Details 3) - Reclassification of Fair Value [Member]	12 Months Ended
	Mar. 31, 2018USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 1,451,393
February 17, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 10 months 20 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	135.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 7,122
July 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	135.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 90,472
June 20, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 2 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	135.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 4,428
April 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	135.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 12,437
November 24, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 7 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	135.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 16,327
December 14, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 8 months 16 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	135.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 85,833
April 21, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 4 months 20 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	118.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 53,853
April 26, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 25 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 11,430
August 8, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 4 months 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 35,722
February 6, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 10 months 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 16,969
February 13, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 10 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 10,703
August 3, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 4 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 109,970
September 1, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	9 years 5 months 5 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 782,966
January 24, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 9 months 25 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value	$ 213,161

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)

Jun. 11, 2018

Sep. 01, 2017

Aug. 03, 2017

Feb. 06, 2017

Aug. 08, 2016

Dec. 14, 2015

Apr. 20, 2018

Jan. 24, 2018

Feb. 13, 2017

Apr. 26, 2016

Apr. 21, 2016

Nov. 24, 2015

Jun. 30, 2018

Mar. 31, 2018

Jun. 30, 2017

Mar. 31, 2018

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

196,044

170,675

170,675

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

7 years 10 months 20 days

5 years 9 months 22 days

7 years 5 months 16 days

5 years 1 month 13 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

7 years 4 months 17 days

5 years 8 months 12 days

5 years 8 months 26 days

6 years 7 days

Fair Value of Shares to be Issued, Stock Options and Warrants

$ 1,451,393

$ 1,451,393

Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 150

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 6,667

Allocated Share-based Compensation Expense

$ 595,412

$ 251,048

1,540,580

$ 844,162

Employees of Bionik Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 150

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

3,334

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,895,000

Allocated Share-based Compensation Expense

17,813

17,813

71,250

66,104

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,667

20,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 213,750

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

2,582,890

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

1,667

Employees of Bionik Inc [Member] | Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 37.50

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

6,667

Employees of Bionik Inc [Member] | Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 142.50

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

6,667

Employees of Bionik Inc [Member] | Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 157.50

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

6,666

Employees of Bionik Inc [Member] | Unvested option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 29,524

0

10,169

102,989

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

24,267

4,334

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1,667

Allocated Share-based Compensation Expense

$ 39,703

35,609

35,609

142,438

142,438

$ 62,317

Fair Value Of Options

$ 491,036

$ 694,384

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.91%

Allocated Share-based Compensation Expense, Net of Tax

27,280

Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 150

Allocated Share-based Compensation Expense

18,113

54,339

$ 217,356

$ 140,230

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

5,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 652,068

Director and Employees and Consultant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

16,634

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

2,912

267

167

Allocated Share-based Compensation Expense

41,350

100,289

$ 479,315

$ 407,208

Fair Value Of Options

$ 1,260,437

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Employee Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 105

Allocated Share-based Compensation Expense

20,433

20,433

81,733

12,163

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

2,667

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 245,200

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 102

Allocated Share-based Compensation Expense

12,396

$ 12,396

49,583

$ 6,345

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

1 year 6 months

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,667

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 148,750

Executive Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

3,334

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 31.50

Allocated Share-based Compensation Expense

7,546

60,371

Fair Value Of Options

$ 387,209

387,209

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share Based Compensation Arrangement By Share Based Payment Award Additional Options Grants In Period Gross

10,000

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.73%

Executive Employee And Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

81,436

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 24.15

Allocated Share-based Compensation Expense

38,173

381,730

Fair Value Of Options

$ 1,832,304

$ 1,832,304

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.91%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

13,573

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

50% of the remaining options vest on performance goals being met and 50% vest over 5 years.

New Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

5,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 6.93

Allocated Share-based Compensation Expense

$ 562

Fair Value Of Options

$ 30,341

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

40,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 9.74

Allocated Share-based Compensation Expense

$ 363,714

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Employees vest equally on January 24, 2019 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 23.25

Employees vest equally on January 24 2020 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

23.25

Employees vest equally on January 24 2021 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 23.25

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants, Outstanding and exercisable, Beginning balance	365,974	117,589	119,336	72,157
Number of Warrants, Issued				48,171
Number of Warrants, Exercised		(33,335)	(1,747)	(992)
Number of Warrants, Outstanding and exercisable, Ending balance	365,974	365,974	117,589	119,336
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 53.19	$ 202.50	$ 202.50	$ 202.50
Weighted-Average Exercise Price, Issued				202.50
Weighted-Average Exercise Price, Exercised		(37.50)	(120)	(120)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 53.19	$ 53.19	$ 202.50	$ 202.50
Broker [Member]
Number of Warrants, Issued		2,667
Weighted-Average Exercise Price, Issued		$ 37.50
Warrant One [Member]
Number of Warrants, Issued		559
Weighted-Average Exercise Price, Issued		$ 112.35
Warrant Two [Member]
Number of Warrants, Issued		6,275
Weighted-Average Exercise Price, Issued		$ 194
Common Shares One [Member]
Number of Warrants, Issued		106,709
Weighted-Average Exercise Price, Issued		$ 9.375
Common Shares Two [Member]
Number of Warrants, Issued		15,658
Weighted-Average Exercise Price, Issued		$ 90
Common Shares Three [Member]
Number of Warrants, Issued		136,388
Weighted-Average Exercise Price, Issued		$ 73.02
Common Shares Four [Member]
Number of Warrants, Issued		13,464
Weighted-Average Exercise Price, Issued		$ 44.28

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 53.19	$ 53.19	$ 202.50	$ 202.50	$ 202.50
Class of Warrant or Right, Number of Warrants	365,974	365,974
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 90	$ 90
Class of Warrant or Right, Number of Warrants	15,658	15,658
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023	Mar. 31, 2023
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 73.02	$ 73.02
Class of Warrant or Right, Number of Warrants	104,019	104,019
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019	Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 73.02	$ 73.02
Class of Warrant or Right, Number of Warrants	21,768	21,768
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019	Mar. 27, 2019
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 73.02	$ 73.02
Class of Warrant or Right, Number of Warrants	5,813	5,813
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019	Mar. 31, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 73.02	$ 73.02
Class of Warrant or Right, Number of Warrants	45,061	45,061
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019	Apr. 21, 2019
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 73.02	$ 73.02
Class of Warrant or Right, Number of Warrants	21,274	21,274
Class Of Warrant Or Right Expiry Date	May 27, 2019	May 27, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 73.02	$ 73.02
Class of Warrant or Right, Number of Warrants	20,782	20,782
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019	Jun. 30, 2019
Warrant Eight [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 44.28	$ 44.28
Class of Warrant or Right, Number of Warrants	22,223	22,223
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019	Feb. 26, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 37.50	$ 37.50
Class of Warrant or Right, Number of Warrants	2,667	2,667
Class Of Warrant Or Right Expiry Date	Jun. 27, 2020	Jun. 27, 2020
Warrant Ten [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.375	$ 9.375
Class of Warrant or Right, Number of Warrants	64,025	64,025
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022	Aug. 14, 2022
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.375	$ 9.375
Class of Warrant or Right, Number of Warrants	42,684	42,684
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022	Mar. 31, 2022

WARRANTS (Details 2)

WARRANTS (Details 2) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Exercise Price	$ 53.19	$ 53.19	$ 202.50	$ 202.50	$ 202.50
Number of Warrants	365,974	365,974
Reclassification Of Employee Stock Options And Warrants [Member]
Number of Warrants		363,307
Remeasured fair value		$ 1,394,164
Warrant One [Member]
Exercise Price	$ 90	$ 90
Number of Warrants	15,658	15,658
Expiry Date	Mar. 31, 2023	Mar. 31, 2023
Warrant One [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 90
Number of Warrants		15,658
Expiry Date		Mar. 31, 2023
Expected life (years)		5 years
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 116,142
Warrant Two [Member]
Exercise Price	$ 73.02	$ 73.02
Number of Warrants	104,019	104,019
Expiry Date	Feb. 26, 2019	Feb. 26, 2019
Warrant Two [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 73.02
Number of Warrants		104,019
Expiry Date		Feb. 26, 2019
Expected life (years)		11 months 1 day
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 100,281
Warrant Three [Member]
Exercise Price	$ 73.02	$ 73.02
Number of Warrants	21,768	21,768
Expiry Date	Mar. 27, 2019	Mar. 27, 2019
Warrant Three [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 73.02
Number of Warrants		21,768
Expiry Date		Mar. 27, 2019
Expected life (years)		1 year
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 24,815
Warrant Four [Member]
Exercise Price	$ 73.02	$ 73.02
Number of Warrants	5,813	5,813
Expiry Date	Mar. 31, 2019	Mar. 31, 2019
Warrant Four [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 73.02
Number of Warrants		5,813
Expiry Date		Mar. 31, 2019
Expected life (years)		1 year
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 6,769
Warrant Five [Member]
Exercise Price	$ 73.02	$ 73.02
Number of Warrants	45,061	45,061
Expiry Date	Apr. 21, 2019	Apr. 21, 2019
Warrant Five [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 73.02
Number of Warrants		45,061
Expiry Date		Apr. 21, 2019
Expected life (years)		1 year 29 days
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 58,358
Warrant Six [Member]
Exercise Price	$ 73.02	$ 73.02
Number of Warrants	21,274	21,274
Expiry Date	May 27, 2019	May 27, 2019
Warrant Six [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 73.02
Number of Warrants		21,274
Expiry Date		May 27, 2019
Expected life (years)		1 year 1 month 28 days
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 32,276
Warrant Seven [Member]
Exercise Price	$ 73.02	$ 73.02
Number of Warrants	20,782	20,782
Expiry Date	Jun. 30, 2019	Jun. 30, 2019
Warrant Seven [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 73.02
Number of Warrants		20,782
Expiry Date		Jun. 30, 2019
Expected life (years)		1 year 3 months
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 36,116
Warrant Eight [Member]
Exercise Price	$ 44.28	$ 44.28
Number of Warrants	22,223	22,223
Expiry Date	Feb. 26, 2019	Feb. 26, 2019
Warrant Eight [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 44.28
Number of Warrants		22,223
Expiry Date		Feb. 26, 2019
Expected life (years)		11 months 1 day
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 38,423
Warrant Ten [Member]
Exercise Price	$ 9.375	$ 9.375
Number of Warrants	64,025	64,025
Expiry Date	Aug. 14, 2022	Aug. 14, 2022
Warrant Ten [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 9.375
Number of Warrants		64,025
Expiry Date		Aug. 14, 2022
Expected life (years)		4 years 4 months 17 days
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 593,355
Warrant Eleven [Member]
Exercise Price	$ 9.375	$ 9.375
Number of Warrants	42,684	42,684
Expiry Date	Mar. 31, 2022	Mar. 31, 2022
Warrant Eleven [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Exercise Price		$ 9.375
Number of Warrants		42,684
Expiry Date		Mar. 31, 2022
Expected life (years)		4 years
Risk free rate		1.59%
Dividend rate		0.00%
Forfeiture rate		0.00%
Expected volatility		135.00%
Remeasured fair value		$ 387,529

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Dec. 31, 2014	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 53.19		$ 53.19		$ 53.19	$ 202.50	$ 202.50	$ 202.50
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	2 years 4 days				2 years 3 months 7 days	1 year 9 months 7 days
Number Of Warrants Exercised					33,335	1,747	992
Stock Issued During Period, Value, Warrants Exercised		$ 1,125,038			$ 1,125,038	$ 40,195
Proceeds from Warrant Exercises	$ 0	1,125,038			$ 1,125,038	$ 40,195
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted							48,171
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ (37.50)	$ (120)	$ (120)
Adjustment To Additional Paid In Capital Warrant Down Feature			$ 0		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued							$ 202.50
Reclassification Of Employee Stock Options And Warrants [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value					$ 1,394,164
Broker [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					2,667
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued					$ 37.50
Warrant One [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 37.50		$ 37.50
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					559
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 112.35
Warrants Issued					2,667
Class of Warrant or Right Expiration Date					Jun. 27, 2020
Warrant One [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 120
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					6,275
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 194
Warrant Two [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					210
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	73.02		73.02		$ 73.02
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					13,464
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 44.28
Warrant Three [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			73.02		$ 73.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value					$ 24,815
Warrant Three [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 112.50
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	73.02		73.02		$ 73.02
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					136,388
Warrant Four [Member] | Reclassification Of Employee Stock Options And Warrants [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 73.02		$ 73.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Reclassified Fair Value					$ 6,769
Third Party Previous Lenders warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Issued					2,331
Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding And Exercisable			34.50		34.50
Common Shares [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants						342
Stock Issued During Period, Shares, Warrants Exercised						1,165
Common Shares One [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 90		$ 90
Warrants Issued					15,658
Class of Warrant or Right Expiration Date					Mar. 31, 2023
Class of Warrant or Right Expiration years					5 years
Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding And Exercisable			90		90
Common Shares Two [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 9.375		$ 9.375
Warrants Issued					106,709
Class of Warrant or Right Expiration Date					Mar. 31, 2023
Retained Earnings [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, Warrants Exercised		$ 0			$ 0	$ 0
Adjustment To Additional Paid In Capital Warrant Down Feature			$ (74,086)		(74,086)
Accrued Liabilities [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt				$ 12,138
Warrant [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 44.25
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations						1,165
Proceeds from Warrant Exercises					$ 1,125,038
Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding And Exercisable			44.28		44.28
Warrant Solicitation [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 37.50		$ 37.50
Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding And Exercisable			37.50		37.50
Investor [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt				$ 180,940

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Components of net loss before income taxes consists of the following:
U.S.	$ (12,281,398)	$ (6,056,384)
Canada	(2,344,392)	(2,013,018)
Net (loss) for the year before recovery of income taxes	$ (14,625,790)	$ (8,069,402)
Statutory rate	34.04%	35.00%
Expected income tax (recovery) expense	$ (4,978,619)	$ (2,824,291)
Tax rate changes and other basis adjustments	1,748,278	44,238
Stock-based compensation	524,412	350,683
Difference in Foreign Tax Rates	184,414	0
Accretion	659,458	0
Share premium	425,497	0
Non-deductible expense	339,296	(132,076)
Net DTA acquired	0	(546,122)
Change in valuation allowance	1,097,264	3,107,568
Recovery of income taxes	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Equipment	$ 70,350	$ 73,520
Share issue costs	510	1,456
SR&ED pool	690,320	464,746
Other	535,510	629,266
Non-capital losses - Canada	2,515,170	2,067,203
Net operating losses - U.S.	4,331,850	4,534,710
Valuation allowance	(7,017,430)	(5,956,118)
Deferred Tax Liabilities, Net, Total	1,126,280	1,814,783
Intangibles and other	(1,126,280)	(1,814,783)
Deferred Tax Assets, Net	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Mar. 31, 2018
Domestic Tax Authority [Member] | United States - Federal [Member]
Income Tax Examination Open Tax Years	2014 – present
Domestic Tax Authority [Member] | United States - State [Member]
Income Tax Examination Open Tax Years	2014 – present
Foreign Tax Authority [Member] | Canada - Federal [Member]
Income Tax Examination Open Tax Years	2013 – present
Foreign Tax Authority [Member] | Canada - Provincial [Member]
Income Tax Examination Open Tax Years	2013 – present

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual)	Mar. 31, 2018USD ($)
Canada
Operating Loss Carryforwards	$ 9,491,200
Parent Company [Member] | UNITED STATES
Operating Loss Carryforwards	6,319,925
Subsidiary [Member] | UNITED STATES
Operating Loss Carryforwards	$ 11,788,800

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	Mar. 06, 2018	May 17, 2017	Feb. 25, 2015	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation				$ 595,412	$ 251,048	$ 1,540,580	$ 1,001,950
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		25.00%
Description Of Contribution For Formation		Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license.
Purchase Commitment, Description	On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at June 30, 2018.
Noncontrolling Interest, Ownership Percentage by Parent		75.00%
Royalty on Sales,Percentage				1.00%		1.00%
Operating Leases, Future Minimum Payments Due, Next Twelve Months				$ 10,083
Operating Leases, Future Minimum Payments, Due in Two Years				13,444
Operating Leases, Future Minimum Payments, Due in Three Years				13,444
Operating Leases, Future Minimum Payments, Due in Four Years				14,141
Operating Leases, Future Minimum Payments, Due in Five Years				14,141
Prepaid Deposits				18,131
Bioniks JV Partner [Member]
Due to Related Parties, Current				$ 93,309
Exchangeable Shares [Member]
Stock Issued During Period, Shares, Issued for Services			1,753
Stock Transferred To Lenders			2,098
Stock to be Reimbursed to Officers			2,134
Proceeds from (Repayments of) Loan			$ 241,185
Share-based Compensation			$ 210,323

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual) - CAD ($)	Jun. 30, 2018	Mar. 31, 2018
Canada [Member] | Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 100,000	$ 100,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

12 Months Ended

Oct. 29, 2018

Sep. 25, 2018

Jul. 20, 2018

Dec. 31, 2017

Jun. 11, 2018

Jun. 30, 2018

Mar. 31, 2018

Mar. 31, 2017

Mar. 31, 2016

Jan. 15, 2017

Dec. 31, 2016

Dec. 31, 2014

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

Common Stock, Shares, Issued

1,652,495

1,368,856

325,901

Common Stock, Shares Authorized

500,000,000

250,000,000

150,000,000

200,000,000

Debt Conversion, Converted Instrument, Shares to be Issued

263,639

263,639

Debt Instrument, Face Amount

$ 0

$ 2,000,000

$ 500,000

$ 500,000

Debt Conversion, Original Debt, Amount

$ 50,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

48,171

Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price

$ (37.50)

$ (120)

$ (120)

Minutes Of Meeting

On July 24, 2018, the Company's Board of Directors (the "Board") unanimously adopted resolutions authorizing a reverse stock split, at a ratio of up to 1:150, of the common stock of the Company. On August 7, 2018, a majority of the holders of the common stock and exchangeable shares of the Company, voting together as a single class, approved the reverse stock split. On September 25, 2018, the Board established the split ratio for the reverse stock split at a ratio of 1:150.

Stockholders' Equity, Reverse Stock Split

Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock split of the common and exchangeable shares.

Scenario, Forecast [Member]

Subsequent Event [Line Items]

Stockholders' Equity, Reverse Stock Split

On October 29, 2018, the Company effected the reverse stock split and thereafter the Company's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.

Warrant One [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

67,952

Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price

$ 73.02

Warrant Two [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

6,305

Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price

$ 44.28

Subsequent Event [Member]

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.00%

Common Stock, Shares Authorized

500,000,000

Debt Instrument, Face Amount

$ 1,960,000

Debt Instrument, Maturity Date

Apr. 30, 2019

Debt Conversion, Original Debt, Amount

$ 4,732,853

Debt Conversion, Converted Instrument, Shares Issued

683,396

Subsequent Event [Member] | Chief Executive Officer [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

40,000

Shares Issued, Price Per Share

$ 9.735

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

7 years

Subsequent Event [Member] | Chief Commercial Officer [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

5,000

Shares Issued, Price Per Share

$ 6.93

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Subsequent Event [Member] | Share Exchange Agreement [Member]

Subsequent Event [Line Items]

Common Stock, Shares, Issued

20,000

Subsequent Event [Member] | Warrant One [Member]

Subsequent Event [Line Items]

Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price

$ 55.71

Subsequent Event [Member] | Warrant Two [Member]

Subsequent Event [Line Items]

Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price

$ 34.50